Illumina Annual Report 2004

Plain-text annual report

06414_AR_Cvr_19 5/6/05 11:00 AM Page 1 I L L U M N A I , I N C . 2 0 0 4 A N N U A L R E P O R T T H E L E A D I N G E D G E O F G E N E T I C A N A LY S I S Illumina, Inc. 9885 Towne Centre Drive San Diego, CA 92121 www.illumina.com 2004 Annual Report 06414_AR_Cvr_20 5/6/05 12:50 PM Page 2 Illumina is keeping customers on the leading edge of research by enabling better performance, higher value, and multiple applications on a single microarray platform. 4 QUARTERS OF SEQUENTIAL REVENUE GROWTH (IN MILLIONS OF DOLLARS) 14 QUARTERS OF SEQUENTIAL REVENUE GROWTH (IN MILLIONS OF DOLLARS) $14.8 $10.7 $10.8 $11.5 $13.5 7 $0.8 $1.3 $1.9 $3.0 $8.2 $3.9 $4.3 $4.8 $14.8 $13.5 $10.7 $10.8 $11.5 $8.2 Q4 2001 Q1 2002 Q2 2002 Q3 2002 Q4 2002 Q1 2003 Q2 2003 Q3 2003 1 $0.7 $0.8 $1.3 $1.9 Q4 2003 $3.0 $3.9 Q1 2004 $4.3 Q2 2004 $4.8 Q3 2004 Q4 2004 Q3 2001 Q4 2001 Q1 2002 Q2 2002 Q3 2002 Q4 2002 Q1 2003 Q2 2003 Q3 2003 Q4 2003 Q1 2004 Q2 2004 Q3 2004 Q4 2004 Corporate Directory Corporate Information BOARD OF DIRECTORS Jay T. Flatley President, Chief Executive Officer and Acting Chief Financial Officer Illumina CORPORATE HEADQUARTERS 9885 Towne Centre Drive San Diego, CA 92121 +1 858.202.4500 www.illumina.com INDEPENDENT ACCOUNTANTS Ernst & Young LLP San Diego, CA 92101 John R. Stuelpnagel, D.V.M. Senior Vice President and Chief Operating Officer Illumina Daniel M. Bradbury Chief Operating Officer Amylin Pharmaceuticals Karin Eastham Executive Vice President and Chief Operating Officer The Burnham Institute Paul Grint, M.D. Senior Vice President and Chief Medical Officer Zephyr Sciences, Inc. William H. Rastetter, Ph.D. Executive Chairman Biogen Idec David R. Walt, Ph.D. Robinson Professor of Chemistry Tufts University EXECUTIVE OFFICERS Jay T. Flatley President, Chief Executive Officer and Acting Chief Financial Officer John R. Stuelpnagel, D.V.M. Senior Vice President and Chief Operating Officer David L. Barker, Ph.D. Vice President and Chief Scientific Officer Paulette D. Cabral Vice President of Human Resources David C. Douglas Vice President of Manufacturing Noemi C. Espinosa Vice President of Intellectual Property Scott D. Kahn, Ph.D. Vice President and Chief Information Officer Robert C. Kain Vice President of Engineering Alan Kersey Vice President and Site General Manager Tristan Orpin Vice President of Worldwide Sales TRANSFER AGENT EquiServe Trust Company N.A. 150 Royall Street Canton, MA 02121 +1 781.575.3400 www.equiserve.com LEGAL COUNSEL Heller Ehrman LLP Menlo Park, CA 94025 FORM 10-K Included with this report is a copy of the Company’s Form 10-K filed with the Securities and Exchange Commission. Additional copies are available by contacting Illumina’s Investor Relations Department. www.illumina.com investor@illumina.com +1 858.202.4750 ANNUAL MEETING The Company’s Annual Meeting of Stockholders will be held at the Company’s corporate headquarters at 10:00 a.m. on June 28, 2005. SELECTED COMMON STOCK DATA The Company’s common stock, par value $.01, has been traded under the symbol ILMN since July 28, 2000 on the NASDAQ National Market. As of May 2, 2005, there were approximately 312 record holders of the Company’s common stock. The Company has not paid any cash dividends since its inception and does not anticipate paying any cash dividends in the foreseeable future. “Safe Harbor” Statement under the Private Securities Litigation Reform Act 1995: this release may contain forward-looking state- ments that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix, the Company’s ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company’s collaboration with Invitrogen, Illumina’s ability to further develop and commercialize its Infinium assay and BeadArray platform technologies, to deploy new gene expression and genotyping products and applications for its platform technolo- gy, to manufacture robust Sentrix® arrays and Oligator® oligonu- cleotides, and other factors detailed in the Company’s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public confer- ence calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward- looking statements beyond the date of this release. © 2005, Illumina, Inc. All rights reserved. Illumina, BeadArray, Array of Arrays, Sentrix, GoldenGate, DASL, Infinium, Making Sense Out of Life and Oligator are trademarks of Illumina, Inc. Printed in the U.S.A. 070-2004-009. By almost any measure, Illumina had a terrific year in 2004. We delivered strong financial results for stockholders and powerful product performance for customers. We ended the year with an exciting pipeline that will drive system and consumable sales growth in 2005 and beyond. We also laid the strategic groundwork for continued long-term success. Throughout the year, our employee team worked tirelessly to execute on an ambitious set of milestones to keep Illumina on the leading edge of genetic analysis. CEO Jay Flatley and on left, John Stuelpnagel, COO. 2004 HIGHLIGHTS We set five specific investor milestones for 2004. A fifth milestone, shipping our multi-sample, The first related to cash burn, with a target of less genome-wide expression arrays, slipped until March than $15 million. Thanks to strong revenue growth of this year, when we announced broad commercial of over 80% compared to 2003 and high gross margins, availability and began putting these products in the we burned just $12 million, ending the year with hands of customers around the world. Our Sentrix $67 million in cash. We aimed to sign 20 genotyping service contracts in 2004 and dramatically exceeded this number by book- Human-6 and HumanRef-8 BeadChips are delivering to the marketplace an industry-leading combination of performance, throughput and value. ing 52 such agreements. Some of these projects were We made several key appointments in 2004 and early quite sizable, requiring tens of millions of genotypes. 2005, naming Karin Eastham and Paul Grint to our This is consistent with an important trend whereby Board of Directors and Bill Rastetter non-executive researchers are forming consortia to combine sample Chairman of the Board. We named Scott Kahn our collections, achieving greater statistical power and new Chief Information Officer, and also promoted increasing their chances of making key discoveries. John Stuelpnagel to Chief Operating Officer. A third milestone related to system sales. We executed well above our 20-system goal, shipping a total of 42 benchtop BeadStations and three production BeadLabs. We now have a global installed base of over 50 systems. In addition, we implemented an upgrade path that allows customers to purchase a BeadStation and then add robotics, LIMS and other components to increase . . . delivering to the marketplace an industry-leading combination of throughput and performance. the level of system automation and the sophistication Before 2004 drew to a close, we signed a significant of sample tracking. Illumina systems and software oligonucleotide collaboration agreement with support a growing list of applications and array formats, Invitrogen Corporation, a large life science company satisfying a broad range of research demands. also located in the San Diego area. Under the terms A fourth milestone involved the International HapMap Project. Illumina was a major project participant, with responsibility for developing assays for approximately 15% of the SNP markers mapped in the Project’s first phase. Over 60% of the total project in this phase was completed using Illumina technology. By the end of 2004, we had developed and screened, along with HapMap partners using Illumina technology, over 600,000 assays compared to our 400,000-assay milestone. The initial scope of the HapMap Project is now closed and the final efforts will be focused on bioinformatical- ly identifying the so-called “tagSNPs” that have the highest value in performing genome-wide scans and disease-association studies. Researchers will soon begin deploying these investigative tools—many of which are based on Illumina assays—to design and conduct bigger projects using larger sample sets, with the potential for truly seminal discovery. of the agreement, Invitrogen will invest $3.4 million in Illumina’s Oligator® DNA synthesis facility to extend our capabilities into tube-based oligos— a segment that is four times larger than the plate- size segment we currently serve. Illumina will turn over all oligo sales and marketing responsibility to Invitrogen, which has approximately 350 salespeople around the world and offices in more than 70 coun- tries. Profits from collaboration products will be split equally between the two companies. We have set a joint target with Invitrogen to achieve annual oligo revenue of $100 million in a few years— far beyond that which either company could have achieved alone. Beyond the ideal strategic fit, this deal allows Illumina to focus all future commercial investments in building out sales and marketing resources to support our genetic analysis systems, arrays and reagents. Researchers can now utilize a single microarray platform and migrate easily from one application to another. We believe we can leverage our investment in infrastructure and technology to accelerate new product development. PRIMING OUR GROWTH Our benchtop BeadStation systems gained good traction This achievement carries a twofold implication. in 2004. We expect to nearly double our installed base in 2005, driven principally by new array products and assay methods. These new applications should also increase reagent consumption at current system locations. First, our customers will benefit from the remarkable flexibility, performance and cost points of Illumina technology. Researchers will be able to utilize a single microarray platform and migrate easily from one One example—introduced in January 2005—is our application to another at varying scales of sample DASL™ assay, a powerful new approach for generating throughput and overall project scope. gene expression profiles from partially degraded RNAs such as those found in formalin-fixed, paraffin- embedded (FFPE) samples. An estimated 400 million FFPE samples exist in North America for cancer alone. Many of these samples represent known clinical outcomes, or endpoints, a potential gold mine of information when linked with the underlying gene expression profiles and an exciting prospect for the validation and testing of biomarkers associated with cancer and other complex diseases. We believe the DASL assay will open up a new avenue for gene expression at high multiplex and low cost per sample. We have the ability to offer SNP content with the highest information value. The implication is equally profound for Illumina. We’ve invested significant resources developing key competencies and fine-tuning our manufacturing infrastructure to support the creation of a very broad portfolio of offerings. We expect to leverage that We plan to launch our Infinium™ assay in the second infrastructure and accelerate cycle times for new quarter. The Infinium assay enables dense genome- product development. For example, we will develop wide genotyping, virtually unconstrained selection and ship two additional whole-genome expression of SNP markers and multiplex levels that are limited products in 2005, one for mouse and one for rat. only by the number of beads on the BeadChip. Our first Infinium product will contain over 100,000 markers, nearly 30,000 of which are located in genes. This product will be ideally suited for large-scale, disease- association studies. Before the middle of 2006, we expect to launch products in this family containing 250,000, 500,000 and 1,000,000 markers. By the middle of this year, Illumina will have developed high-value assay and bead-based array products that support both genotyping and gene expression, with whole-genome and focused approaches, fixed and custom content, and on two different BeadArray™ platforms: the Array Matrix and the BeadChip. SETTING THE STAGE TO ENTER NEW MARKETS BEYOND THE NUMBERS A number of our 2004 system sales include associated Beside financial measures, one of our most important agreements that provide rights to biomarkers discov- measures of success and, in fact, a hallmark of the ered and validated with Illumina technology. These Illumina brand, is the relationships we build with agreements are the beginning of a commercial strategy customers. We’re highly focused on building collabora- that will take advantage of emerging market opportu- tive interactions and doing so in the context of helping nities involving the use of microarrays for clinical scientists generate compelling results. research and molecular diagnostics. Fundamental to our success is our employee team. In April of this year, we took another critical step We are continually impressed both by the innovation in that direction with our acquisition of CyVera and the sheer dedication of our human resources. Corporation. CyVera is developing a digital microbead platform that is highly complementary with our existing BeadArray technology. CyVera’s rod-shaped beads can support both nucleic acid and protein probe content. The tech- nology is ideally suited to address the growing markets As we developed our new whole-genome offerings and expanded manufacturing capabilities over the past year, we asked much of our employees. In every case, they have responded and risen to each chal- lenge—underscoring the power of our shared goal of enabling personalized medicine. in low to mid-multiplex applications, ranging from ten In closing, we’d like to quote a large customer who to 1000 targets—a perfect complement to Illumina’s characterized Illumina as “. . . the group of the future. denser microarray solutions that offer multiplex levels Their technology is outstanding, their accuracy and of 384 to over 200,000 targets. precision is superb and the customer service is CyVera technology will be integrated into an expanded incredibly responsive.” portfolio of offerings based on BeadArray technology We aim to keep it that way. and high-performance assay solutions. The first prod- ucts from CyVera are expected to be available in the second half of 2006. As a result, Illumina will be posi- tioned to offer a comprehensive approach to biomarker discovery and in-vitro and molecular diagnostic mar- kets, including those that require low as well as high- complexity testing. The emerging molecular diagnostic market is an excit- ing opportunity with significant revenue potential. In order to best leverage our technology and capture significant value from this opportunity, we will seek collaborators and partners with a strong breadth and depth of experience in the diagnostics market. Thank you for your ongoing support. JAY T. FLATLEY President, Chief Executive Officer and Acting Chief Financial Officer JOHN R. STUELPNAGEL, D.V.M. Senior Vice President and Chief Operating Officer Invitrogen will invest $3.4 million in Illumina's Oligator ® facility to extend DNA synthesis capability into tube-based products. 2004 RESULTS: form 10-K > SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ﬁscal year ended January 2, 2005 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . ¥ n Commission ﬁle number: 000-30361 Illumina, Inc. (Exact name of Registrant as Speciﬁed in Its Charter) Delaware (State or other Jurisdiction of Incorporation or Organization) 9885 Towne Centre Drive, San Diego, California (Address of Principal Executive Ofﬁces) 33-0804655 (I.R.S. Employer Identiﬁcation No.) 92121 (zip code) Registrant’s telephone number, including area code: (858) 202-4500 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.01 par value (Title of class) Indicate by check mark whether the Registrant (1) has ﬁled all reports required to be ﬁled by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to ﬁle such reports), and (2) has been subject to such ﬁling requirements for the past 90 days. Yes ¥ No n Indicate by check mark if disclosure of delinquent ﬁlers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in deﬁnitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. n Indicate by check mark whether the registrant is an accelerated ﬁler (as deﬁned in Rule 12b-2 of the Act). Yes ¥ No n As of January 31, 2005, there were 38,124,708 shares of the Registrant’s Common Stock outstanding. The aggregate market value of the Common Stock held by non-afﬁliates of the Registrant (based on the closing price for the Common Stock on the Nasdaq National Market on June 30, 2004) was approximately $211,848,212. This amount excludes an aggregate of 4,291,431 shares of common stock held by ofﬁcers and directors and each person known by the Registrant to own 10% or more of the outstanding common stock. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the Registrant, or that such person is controlled by or under common control with the Registrant DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s deﬁnitive proxy statement for the annual meeting of stockholders expected to be held on May 19, 2005 are incorporated by reference into Part III of this Report. ILLUMINA, INC. FORM 10-K For the ﬁscal year ended JANUARY 2, 2005 TABLE OF CONTENTS Item 1 Item 2 Item 3 Item 4 Business******************************************************************** Properties ****************************************************************** Legal Proceedings*********************************************************** Submission of Matters to a Vote of Security Holders **************************** PART I PART II Item 5 Item 6 Item 7 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ************************************************ Selected Financial Data ****************************************************** Management’s Discussion and Analysis of Financial Condition and Results of Operation ****************************************************************** Item 7A Quantitative and Qualitative Disclosures about Market Risk ********************** Financial Statements and Supplementary Data ********************************* Item 8 Changes in and Disagreements with Accountants on Accounting and Financial Item 9 Disclosure ****************************************************************** Item 9A Controls and Procedures ***************************************************** Item 9B Other Information *********************************************************** PART III Item 10 Directors and Executive Ofﬁcers of the Registrant ****************************** Executive Compensation ***************************************************** Item 11 Security Ownership of Certain Beneﬁcial Owners and Management*************** Item 12 Certain Relationships and Related Transactions ********************************* Item 13 Principal Accounting Fees and Services **************************************** Item 14 Page 2 16 16 18 18 20 21 43 44 44 44 45 46 46 46 47 47 Exhibits, Financial Statement Schedules**************************************** Item 15 Signatures**************************************************************************** Financial Statements ****************************************************************** 48 52 F-1 PART IV 1 Item 1. Business. PART I This Annual Report on Form 10-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or our future ﬁnancial performance. We have attempted to identify forward-looking statements by terminology including ‘‘anticipates,’’ ‘‘believes,’’ ‘‘can,’’ ‘‘con- tinue,’’ ‘‘could,’’ ‘‘estimates,’’ ‘‘expects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘plans,’’ ‘‘potential,’’ ‘‘predicts,’’ ‘‘should’’ or ‘‘will’’ or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under ‘‘Factors Affecting Operating Results,’’ contained in Item 7 — ‘‘Management’s Discus- sion and Analysis of Financial Condition and Results of Operation,’’ that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reﬂected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We are not under any duty to update any of the forward-looking statements after the date we ﬁle this Annual Report on Form 10-K or to conform these statements to actual results, unless required by law. Illumina˛, Array of ArraysTM, BeadArrayTM, DASLTM, GoldenGate˛, InﬁniumTM, Sentrix˛ and Oligator˛ are our trademarks. This report also contains brand names, trademarks or service marks of companies other than Illumina, and these brand names, trademarks and service marks are the property of their respective holders. Available Information Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports are available free of charge on our website, www.illumina.com. The information on our website is not incorporated by reference into this report. Such reports are made available as soon as reasonably practicable after ﬁling with the Securities and Exchange Commission. The SEC also maintains an Internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that electronically ﬁle with the SEC. Overview We are a leading developer and marketer of next-generation tools for the large-scale analysis of genetic variation and function. Understanding genetic variation and function is critical to the develop- ment of personalized medicine, a key goal of genomics. Our tools provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The sequencing of the human genome has driven demand for tools that can assist researchers in processing the billions of tests necessary to convert raw genetic data into medically valuable information. This requires functional analysis of highly complex biological systems, involving a scale of experimentation not previously practical. Using our technologies, we have developed a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to help achieve the goals of molecular medicine. 2 Our patented BeadArray technology uses microscopic beads randomly deposited in wells to achieve a level of miniaturization that allows for a new scale of experimentation. A microarray is a collection of miniaturized test sites arranged on a surface that permits many tests, or assays, to be performed in parallel. We assemble our arrays using relatively inexpensive materials. Our proprietary manufacturing process allows us to easily adapt the arrays to a broad range of applications, including both genotyping and gene expression. These characteristics allow us to create next-generation arrays with a unique combination of high throughput, cost effectiveness and ﬂexibility. In addition, our complementary Oligator technology permits parallel synthesis of the millions of different pieces of DNA necessary to perform large-scale genetic analysis on arrays. We provide both products and services that utilize our proprietary technologies. During 2001, we launched our commercial genotyping service product line which combines our BeadArray technology with an automated, laboratory information management system, or LIMS, controlled process to provide high throughput identiﬁcation of the most common form of genetic variation, known as single nucleotide polymorphisms, or SNPs. We also began the sale of custom synthesized pieces of DNA called oligonucleotides, or oligos, using our proprietary Oligator technology. In 2002, we announced the launch of our production-scale BeadLab. This integrated turnkey system is built around our proprietary BeadArray technology. Included in the system are the BeadArray Reader, GoldenGate assay protocols, LIMS and analytical software, ﬂuid-handling robotics, and access to Sentrix arrays and our reagent kits for analyzing genetic sequences. Our Sentrix Array Matrix is a collection of individual arrays arranged in an Array of Arrays pattern compatible with standard microtiter plates, our reagent kit uses highly multiplexed GoldenGate assay protocols which allow up to 1536 SNPs to be analyzed at one time in a sample and our BeadArray Reader is a proprietary scanner used to read the results of the experiments captured on our arrays. When installed, the BeadLab is able to routinely produce up to 1.4 million genotypes per day. Also in 2002, we were named the largest U.S. participant in the $100 million ﬁrst phase of the International HapMap Project funded by the National Institutes of Health. This project is an internation- ally funded successor project to the Human Genome Project that is creating a map of genetic variations that may be used to perform disease-related research. This map of the human genome will allow more rapid and efﬁcient large-scale genetic association studies aimed at discovering variants contributing to human disease and differential response to drug treatments. We are one of ﬁve funded ﬁrst phase U.S. participants in a worldwide initiative that includes research groups in Canada, China, Japan, Nigeria and the United Kingdom. We are directly responsible for screening over 15% of the assays in the ﬁrst phase of this project. This effort leverages our Oligator DNA synthesis capability and the production-scale throughput of our genotyping services operation. Our BeadLab is being used by organizations responsible for creating over 60% of the assays in the ﬁrst phase of this project, which we expect to be completed in early 2005. In early 2003, we completed the installation of and recorded revenue for our ﬁrst BeadLab, and as of January 2, 2005, we have installed nine BeadLabs. In 2003, we announced the launch of several new products, including 1) a new array format, the Sentrix BeadChip, which signiﬁcantly expands market opportunities for our BeadArray technology and provides increased experimental ﬂexibility for life science researchers; 2) a gene expression product line on both the Sentrix Array Matrix and the Sentrix BeadChip that allows researchers to analyze a focused set of genes across eight to 96 samples on a single array; and 3) a benchtop SNP genotyping and gene expression system, the BeadStation, for performing moderate-scale genotyping and gene expression using our technology. The BeadStation includes our BeadArray Reader, analysis software and assay reagents and is designed to match the throughput requirements and variable automation needs of individual research groups and core labs. Sales of these products began in early 2004 and, as of January 2, 2005, we have shipped 42 BeadStations. 3 In 2004, we announced the launch of new Sentrix BeadChips for whole-genome gene expression and whole-genome genotyping. The whole-genome gene expression BeadChips are designed to enable high-performance, cost-effective, whole-genome expression proﬁling of multiple samples on a single chip, resulting in a dramatic reduction in cost of whole-genome expression analysis while allowing researchers to expand the scale and reproducibility of large-scale biological experimentation. The whole-genome genotyping BeadChip can be scaled to unlimited levels of multiplexing without compromising data quality and will provide scientists the ability to query, in parallel, a high-value set of over 100,000 SNPs. In 2004, we also announced two new versions of the Sentrix Array Matrix designed for researchers who want to take advantage of our technology, but whose projects require fewer SNPs per sample than the number utilized on our standard 1536-plex array products. In late 2004, we announced a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. Under the agreement, we intend to expand our Oligator DNA synthesis technology, and Invitrogen will be responsible for sales, marketing and technical support. Proﬁts from sales of collaboration products will be divided equally between the two companies. In early 2005, we expanded our gene expression portfolio by announcing the launch of a new assay, DASL, for generating gene expression proﬁles from RNA samples including those containing partially degraded RNAs. We also announced a standard DASL cancer panel. Prior to our DASL assay, degraded RNA samples have been reliably assayed only with expensive, low-multiplex approaches. In February 2005, we signed a deﬁnitive agreement and plan of merger with CyVera Corporation, a privately-held Connecticut-based company, pursuant to which CyVera will become a wholly-owned subsidiary of Illumina. CyVera’s digital-microbead platform is highly complementary to our portfolio of products and services and upon closing of the transaction, will become an integral part of our BeadArray technology. The acquisition is expected to provide us with a comprehensive approach to bead-based assays for biomarker R&D and in-vitro and molecular diagnostic opportunities, including those that require low-complexity as well as high-complexity testing. The aggregate consideration for the transaction is $17.5 million, consisting of approximately 1.5 million shares of Illumina common stock and the payment of approximately $2.3 million of CyVera’s liabilities at the closing. The closing is subject to customary closing conditions and is expected to occur by the end of March 2005. We expect the ﬁrst products based on CyVera’s technology to be available in the second half in 2006. We are seeking to expand our customer base for our BeadArray technology; however, we can give no assurance that our sales efforts will continue to be successful. We were incorporated in California in April 1998. We reincorporated in Delaware in July 2000. Our principal executive ofﬁces are located at 9885 Towne Centre Drive, San Diego, California 92121. Our telephone number is (858) 202-4500. Industry Background Genetic Variation and Function Every person inherits two copies of each gene, one from each parent. The two copies of each gene may be identical, or they may be different. These differences are referred to as genetic variation. Examples of the physical consequences of genetic variation include differences in eye and hair color. Genetic variation can also have important medical consequences, including predisposition to disease and differential response to drugs. Genetic variation affects diseases, including cancer, diabetes, cardiovascular disease and Alzheimer’s disease. In addition, genetic variation may cause people to respond differently to the same drug. Some people may respond well, others may not respond at all, and still others may experience adverse side effects. The most common form of genetic variation is a Single Nucleotide Polymorphism, or SNP. A SNP is a variation in a single position in a DNA sequence. It is estimated that the human genome contains between three and six million SNPs. 4 While in some cases a single SNP will be responsible for medically important effects, it is now believed that the genetic component of most major diseases is the result of the interaction of many SNPs. Therefore, it is important to investigate many SNPs together in order to discover medically valuable information. Current efforts to understand genetic variation and function have primarily centered around SNP genotyping and gene expression proﬁling. SNP Genotyping SNP genotyping is the process of determining which SNPs are present in each of the two copies of a gene, or other portion of DNA sequence, within an individual or other organism. The use of SNP genotyping to obtain meaningful statistics on the effect of an individual SNP or a collection of SNPs, and to apply that information to clinical trials and diagnostic testing, requires the analysis of millions of SNP genotypes and the testing of large populations for each disease. For example, a single large clinical trial could involve genotyping 200,000 SNPs per patient in 1,000 patients, thus requiring 200 million assays. Using previously available technologies, this scale of SNP genotyping was both impractical and prohibitively expensive. Large-scale SNP genotyping will be used for a variety of applications, including genomics-based drug development, clinical trial analysis, disease predisposition testing, and disease diagnosis. SNP genotyping can also be used outside of healthcare, for example in the development of plants and animals with desirable commercial characteristics. These markets will require billions of SNP genotyp- ing assays annually. Gene Expression Proﬁling Gene expression proﬁling is the process of determining which genes are active in a speciﬁc cell or group of cells and is accomplished by measuring mRNA, the intermediary between genes and proteins. Variation in gene expression can cause disease, or act as an important indicator of disease or predisposition to disease. By comparing gene expression patterns between cells from different environments, such as normal tissue compared to diseased tissue or in the presence or absence of a drug, speciﬁc genes or groups of genes that play a role in these processes can be identiﬁed. Studies of this type, used in drug discovery, require monitoring thousands, and preferably tens of thousands, of mRNAs in large numbers of samples. Once a smaller set of genes of interest has been identiﬁed, researchers can then examine how these genes are expressed or suppressed across numerous samples, for example, within a clinical trial. The high cost of current gene expression methods has limited the development of the gene expression market. As gene expression patterns are correlated to speciﬁc diseases, gene expression proﬁling is becoming an increasingly important diagnostic tool. Diagnostic use of expression proﬁling tools is anticipated to grow rapidly with the combination of the sequencing of various genomes and the availability of more cost-effective technologies. 5 Our Technologies BeadArray Technology We have developed a proprietary array technology that enables the large-scale analysis of genetic variation and function. Our BeadArray technology combines microscopic beads and a substrate in a simple proprietary manufacturing process to produce arrays that can perform many assays simultane- ously. Our BeadArray technology provides a unique combination of high throughput, cost effective- ness, and ﬂexibility. We achieve high throughput with a high density of test sites per array and our ability to format arrays in either a pattern arranged to match the wells of standard microtiter plates or in various conﬁgurations in the format of standard microscope slides. We maximize cost effectiveness by reducing consumption of expensive reagents and valuable samples, and from the low manufacturing costs associated with our technologies. Our ability to vary the size, shape and format of the well patterns and to create speciﬁc bead pools, or sensors, for different applications provides the ﬂexibility to address multiple markets and market segments. We believe that these features have enabled our BeadArray technology to become a leading platform for the emerging high-growth market of SNP genotyping and expect they will enable us to become a key player in the gene expression market. Our proprietary BeadArray technology combines microwells etched into a substrate and specially prepared beads that self-assemble into an array. We have deployed our BeadArray technology in two different Sentrix array formats, the Array Matrix and the BeadChip. Our ﬁrst bead-based product was the Array Matrix which incorporates ﬁber optic bundles. We have the ﬁber optic bundles manufactured to our speciﬁcations, which we cut into lengths of less than one inch. Each bundle contains approximately 50,000 individual ﬁbers and 96 of these bundles are placed into an aluminum plate, which forms an Array Matrix. BeadChips are fabricated in microscope slide-shaped sizes with varying numbers of sample sites per slide. Both formats are chemically etched to create tens of thousands of wells for each sample site. In a separate process, we create sensors by afﬁxing a speciﬁc type of molecule to each of the billions of microscopic beads in a batch. We make different batches of beads, with the beads in a given batch coated with one particular type of molecule. The particular molecules on a bead deﬁne that bead’s function as a sensor. For example, we create a batch of SNP sensors by attaching a particular DNA sequence to each bead in the batch. We combine batches of coated beads to form a pool speciﬁc to the type of array we intend to create. A bead pool one milliliter in volume contains sufﬁcient beads to produce thousands of arrays. One of the advantages of this technology is that it allows us to create universal arrays for SNP genotyping, and by varying the reagent kit, still be able to use the array to test for any combination of SNPs. To form an array, a pool of coated beads is brought into contact with the array surface where they are randomly drawn into the wells, one bead per well. The tens of thousands of beads in the wells comprise our individual arrays. Because the beads assemble randomly into the wells, we perform a ﬁnal procedure called decoding in order to determine which bead type occupies which well in the array. We employ several proprietary methods for decoding, a process that requires only a few steps to identify all the beads in the array. One beneﬁcial by-product of the decoding process is a validation of each bead in the array. This quality control test characterizes the performance of each bead and can identify and eliminate use of any empty wells. We ensure that each bead type on the array is sufﬁciently represented by having multiple copies of each bead type. This improves the reliability and accuracy of the resulting data by allowing statistical processing of the results of identical beads. 6 An experiment is performed on the Array Matrix by preparing a sample, such as DNA from a patient, and introducing it to the array. The design features of our Array Matrix allow it to be simply dipped into a solution containing the sample, whereas our BeadChip allows processing of samples on a slide. The molecules in the sample bind to their matching molecules on the coated bead. The BeadArray Reader detects the matched molecules by shining a laser on the ﬁber optic bundle or on the BeadChip. Since the molecules in the sample have a structure that causes them to emit light in response to a laser, detection of a binding event is possible. This allows the measurement of the number of molecules bound to each coated bead, resulting in a quantitative analysis of the sample. Oligator Technology Genomic applications require many different short pieces of DNA that can be made synthetically, called oligonucleotides. For example, SNP genotyping typically requires three to four different oligonucleotides per assay. A SNP genotyping experiment analyzing 10,000 SNPs may therefore require 30,000 to 40,000 different oligonucleotides, contributing signiﬁcantly to the expense of the experiment. We have designed our proprietary Oligator technology for the parallel synthesis of many different oligonucleotides to meet the requirements of large-scale genomics applications. We believe that our Oligator technology is substantially more cost effective and provides higher throughput than available commercial alternatives. Our synthesis machines are computer controlled and utilize many robotic processes to minimize the amount of labor used in the manufacturing process. Each of these synthesizers can produce up to 3072 oligos in parallel, using very small amounts of material. We believe both of these attributes are substantial improvements over other existing technologies. In 2005, we intend to implement fourth-generation Oligator technology which will further expand our production capabilities and extend our technology into tube-based oligo products. Key Advantages of Our BeadArray and Oligator Technologies We believe that our BeadArray and Oligator technologies provide distinct advantages, in a variety of applications, over competing technologies, by creating cost-effective, highly miniaturized arrays with the following advantages: High Throughput. The miniaturization of our BeadArray technology provides signiﬁcantly greater information content per unit area than any other array known to us. To further increase throughput, we have formatted our arrays in a pattern arranged to match the wells of standard microtiter plates, allowing throughput levels of up to 150,000 unique assays per microtiter plate, as well as the use of laboratory robotics to speed process time. The Oligator’s parallel synthesis capability allows us to manufacture the diversity of oligonucleotides necessary to support large-scale genomic applications. Cost Effectiveness. Our array products substantially reduce the cost of experiments as a result of our proprietary manufacturing process and our ability to capitalize on cost reductions generated by advances in ﬁber optics, digital imaging and bead chemistry. In addition, these products require smaller reagent volumes than other array technologies, and therefore reduce reagent costs. Our cost- effective Oligator technology further reduces reagent costs, as well as the cost of coating beads. Flexibility. A wide variety of conventional chemistries are available for attaching different molecules, such as DNA, RNA, proteins, and other chemicals to beads. By using beads, we are able to take advantage of these chemistries to create a wide variety of sensors, which we assemble into arrays using the same proprietary manufacturing process. In addition, we can have ﬁber optic bundles and BeadChips manufactured in multiple shapes and sizes with wells organized in various arrangements to optimize them for different markets and market segments. In combination, the use of beads and etched wells provides the ﬂexibility and scalability for our BeadArray technology to be tailored to perform many applications in many different market segments, from drug discovery to diagnostics. Our Oligator technology allows us to manufacture a wide diversity of lengths and quantities of oligonucleotides. 7 Quality. The high density of beads in each array enables us to have multiple copies of each individual bead type. We measure the copies simultaneously and combine them into one data point. This allows us to make a comparison of each bead against its own population of identical beads, which permits the statistical calculation of a more reliable and accurate value for each data point. Finally, the manufacture of the array includes a proprietary decoding step that also functions as a quality control test of every bead on every array, improving the overall quality of the data. Our Strategy Our goal is to make our BeadArray platforms the industry standard for products and services utilizing array technologies. We plan to achieve this by: ) focusing on emerging high-growth markets; ) rapidly commercializing our BeadLab, BeadStation, Sentrix Array Matrix and BeadChip products; ) expanding our technologies into multiple product lines and market segments; and ) strengthening our technological leadership. Products and Services The ﬁrst implementation of our BeadArray technology, the Sentrix Array Matrix, is a disposable matrix with 96 ﬁber optic bundles arranged in a pattern that matches the standard 96-well microtiter plate. Each ﬁber optic bundle performs more than 1,500 unique assays. Therefore, one Sentrix Array Matrix can perform nearly 150,000 individual assays simultaneously, more than any other commercial array system known to us. The BeadChip, introduced in 2003, is fabricated in multiple conﬁgurations to support multiple applications and scanning technologies. We have provided genotyping services using our proprietary BeadArray technology since 2001. In addition, we have developed our ﬁrst genotyping and gene expression products based on this technology. These products include disposable Sentrix Array Matrices and BeadChips, GoldenGate reagent kits for SNP genotyping, BeadArray Reader scanning instruments and an evolving portfolio of custom and standard gene expression products. SNP Genotyping In 2001, we introduced the ﬁrst commercial application of our BeadArray technology by launching our SNP genotyping services product line. Since this launch we have had peak days in which we operated at over two million genotypes per day based on individual samples. To our knowledge, no other genotyping platform can achieve comparable levels of throughput while delivering such high accuracy and low cost. We designed our ﬁrst consumable BeadArray product, the Sentrix Array Matrix, for SNP genotyp- ing. The Sentrix Array Matrix uses a universal format that allows it to analyze any set of SNPs. We have also developed reagent kits based on GoldenGate assay protocols and the BeadArray Reader, a laser scanner, which is used to read our array products. Depending on throughput and automation requirements, our customers can select the system conﬁguration to best meet their needs. For production-scale throughput, our BeadLab would be appropriate, and for moderate-scale throughput, our BeadStation would be selected. Our BeadLab includes our BeadArray Reader, combined with LIMS, standard operating procedures and analytical software and ﬂuid handling robotics. This production-scale system was commercialized in late 2002 and when installed, this system can routinely produce up to 1.4 million genotypes per day. 8 The BeadStation, a system for performing moderate-scale genotyping designed to match the throughput requirements of individual research groups and core labs, was commercialized in late 2003. The BeadStation includes our BeadArray Reader and genotyping and/or gene expression analysis software. Our BeadStations are fully upgradeable to a full BeadLab through various steps that add automation, sample preparation equipment and LIMS capability. For use in SNP genotyping, both the BeadLab and BeadStation utilize GoldenGate assay reagents and our Array Matrices and will soon support a high-density version of our BeadChip. The Sentrix BeadChip allows simultaneous processing of 16 samples and uses identical content as the Sentrix Array Matrix. Also in 2003, we announced the availability of an assay set for genetic linkage analysis. This standard product has been deployed in our genotyping services operation and is also sold to customers who use our SNP genotyping systems. Genetic linkage analysis can help identify chromo- somal regions with potential disease associations across a related set of samples. In 2004, we announced a new Sentrix BeadChip for whole-genome genotyping. This BeadChip will provide scientists the ability to interrogate over 100,000 SNPs located in high-value genetic regions of the human genome. Gene Expression Proﬁling With the addition of application speciﬁc accessory kits, our production-scale BeadLabs and BeadStations are capable of performing a growing number of applications including gene expression proﬁling. In 2003, we introduced our focused set gene expression products on both the Sentrix Array Matrix and Sentrix BeadChip platforms. For high-throughput projects, our system includes a BeadArray Reader for imaging Sentrix Array Matrices and BeadChips, a hybridization chamber and software for data extraction. For research projects that require moderate throughput, a version of the Sentrix BeadChip analyzes eight samples in parallel and can be scanned on a portion of the installed base of Axon Instruments’ GenePixTM scanners. In addition, we have developed standard gene expression products for each of the human, mouse and arabidopsis genomes. In 2004, we announced the Sentrix Human-6 and HumanRef-8 Expression BeadChip products. Both products will allow large-scale expression proﬁling of multiple samples on a single chip and are imaged using our BeadArray Reader. The Human-6 BeadChip is designed to analyze six discrete whole-human-genome samples on one chip, interrogating in each sample approximately 48,000 transcripts from the estimated 30,000 genes in the human genome. The HumanRef-8 BeadChip product analyzes eight samples in parallel against 24,000 transcripts from the roughly 22,000 genes represented in the consensus RefSeq database, a well-characterized whole-genome subset used broadly in genetic analysis. We expect that these new gene expression BeadChips will dramatically reduce the cost of whole-genome expression analysis, allowing researchers to expand the scale and reproducibility of large-scale biological experimentation. In early 2005, we introduced the new DASL assay for generating gene expression proﬁles from RNA samples, including formalin-ﬁxed, parafﬁn-embedded (FFPE) samples and other samples contain- ing degraded RNAs. The DASL assay enables researchers to measure RNA abundance of over 500 genes in parallel per sample. We also released a standard DASL cancer panel. It has been estimated that there are over 400 million FFPE tissue samples archived in North America for cancer alone. Many of these samples represent known clinical outcomes which will yield important information when linked with underlying gene expression proﬁles. To date, degraded RNA samples have been reliably assayed only with expensive, low-multiplex approaches. Our DASL assay generates RNA proﬁles at high multiplex and at a low cost per sample as compared to existing technologies. 9 Scanning Instrumentation The BeadArray Reader, an instrument we developed, is a key component of both our production- scale BeadLab and our benchtop BeadStation. This scanning equipment uses a laser to read the results of experiments that are captured on our arrays and was designed to be used in all areas of genetic analysis that use our Sentrix Array Matrices and Sentrix BeadChips. High-Throughput Synthesis We have put in place an oligonucleotide manufacturing facility that currently has the capability of producing approximately 20 million oligonucleotides per year. In addition to their use to coat beads, these oligonucleotides are components of the reagent kits for our BeadArray products and are used for assay development. Because our production capacity exceeds our internal needs, we began to offer oligonucleotides for sale to high volume users in 2001. We provide oligonucleotides in a wide range of lengths and in several scales, with the ability to add many types of modiﬁcations. We offer a range of quality control options and have implemented a laboratory information management system to control much of the manufacturing process. In 2003, we introduced the ﬁrst standard product offerings in our Oligator product line, a whole-genome oligonucleotide reference set designed and optimized for spotted gene expression microarrays, and in 2004, we introduced a mouse genome oligo set, also for use on spotted gene expression arrays. We believe our Oligator technology is more cost effective than competing technologies, which has allowed us to market our oligonucleotides under a price leadership strategy while still achieving attractive gross margins. In 2005, in connection with a collaboration agreement with Invitrogen Corporation, we intend to implement fourth-generation Oligator technol- ogy which will further expand our production capabilities and extend our technology into tube-based oligo products. Collaboration with Invitrogen Corporation In December 2004, we entered into a strategic collaboration with Invitrogen Corporation. Through this collaboration, we intend to expand our Oligator DNA synthesis technology and combine that capability with Invitrogen’s sales, marketing and distribution channels. Under the terms of the agreement, Invitrogen has agreed to pay us up to $3.4 million, which we plan to invest in our San Diego facility to enable implementation of fourth-generation Oligator technology and extend the technology into tube-based oligo products. In addition, the agreement provides for the transfer of our Oligator technology into two Invitrogen facilities outside North America. Proﬁt from the sale of collaboration products will be divided equally between the two companies. Research and Development We have made substantial investments in research and development since our inception. We have assembled a team of skilled engineers and scientists who are specialists in biology, chemistry, informatics, instrumentation, optical systems, software, manufacturing and other related areas required to complete the development of our products. Our research and development efforts have focused primarily on the tasks required to optimize our BeadArray and Oligator technologies and to support commercialization of the products and services derived from these technologies. These efforts include among others: ) We enhanced the quality and manufacturing yield of our Sentrix Array Matrices and BeadChips. We are exploring ways to continue to increase the level of automation in the manufacturing process to further reduce the time and cost of producing arrays. We currently have the infrastructure in place to manufacture Sentrix Array Matrices and BeadChips in sufﬁcient quantity to meet anticipated internal and external needs. 10 ) We introduced a number of initiatives in 2002 and 2003 to improve the yield and quality of our oligonucleotides while reducing cost substantially. By reﬁning our understanding of the design and operation of our Oligator technology, we have been able to make numerous changes in our process, which we believe provides us a more cost effective system than competing technolo- gies. Our oligonucleotide manufacturing facility currently has the capability of producing approximately 20 million oligonucleotides per year. In 2005, we intend to expand our Oligator technology under a collaboration agreement with Invitrogen Corporation. This expansion will enable implementation of fourth-generation Oligator technology and extend the technology into tube-based oligo products. ) We have developed the BeadArray Reader, a laser scanning instrument that scans our Sentrix array platforms. Laser scanners provide the high sensitivity and resolution required to address the extremely dense geometries of our bead-based arrays. We made the ﬁrst commercial shipments of our scanners in the ﬁrst quarter of 2003 as part of our BeadLab. ) We completed development of and launched our Direct Hyb and DASL gene expression assays on both array formats. We believe the combination of our gene expression products ﬂexibility and low-per-sample cost will enable larger and more meaningful gene expression studies. ) We have signed a deﬁnitive agreement to acquire CyVera Corporation, a company whose technology is highly complementary to our portfolio of products and services and upon closing of the transaction will become an integral part of our BeadArray technology. The acquisition is expected to provide us with a comprehensive approach to bead-based assays for biomarker R&D and in-vitro and molecular diagnostic opportunities, including those that require low- complexity as well as high-complexity testing. ) We have been exploring the underlying molecular biology and chemistry issues related to developing assays and performing experiments on our BeadArray platforms. By improving our processes and protocols, we have substantially increased the number of assays we can process simultaneously in a single sample on our arrays. Our research and development expenses for the ﬁscal years 2004, 2003 and 2002 (exclusive of charges relating to stock based compensation of $0.8 million, $1.3 million and $2.4 million, respec- tively) were $21.1 million, $22.5 million and $26.8 million, respectively. We expect research and development expense to increase in 2005 as compared to 2004 as we continue to expand our research and product development efforts. Government Grants Government grants allow us to fund internal scientiﬁc programs and exploratory research. We retain ownership of all intellectual property and commercial rights generated during these projects, subject to a non-exclusive, non-transferable, paid-up license to practice, for or on behalf of the United States, inventions made with federal funds. This license is retained by the U.S. government as provided by applicable statutes and regulations. We do not believe that the retained license will have any impact on our ability to market our products, and we do not need government approval with respect to this license in order to enter into collaborations or other relationships with third parties. We are the recipient of a grant from the National Institutes of Health covering our participation in the ﬁrst phase of the International HapMap Project, which is a $100.0 million, internationally funded successor project to the Human Genome Project that will help identify a map of genetic variations that may be used to perform disease-related research. We could receive up to $9.1 million of funding for this project which covers basic research activities, the development of SNP assays and the genotyping to be performed on those assays. As of the end of 2004, we had approximately $0.7 million of funding remaining related to this project, which is expected to be received in early 2005. 11 Intellectual Property We have an extensive patent portfolio, including ownership of, or exclusive licenses to, 29 issued U.S. patents and 76 pending U.S. patent applications, including seven allowed applications that have not yet issued as patents, some of which derive from a common parent application. Our issued patents, which cover various aspects of our BeadArray, oligonucleotide synthesis and chemical detection technologies, expire between 2011 and 2020. We are seeking to extend this patent protection on our BeadArray, GoldenGate, Oligator, Sentrix and related technologies. We have received or ﬁled counterparts for many of these patents and applications in one or more foreign countries. We also rely upon trade secrets, know-how, copyright and trademark protection, as well as continuing technological innovation and licensing opportunities to develop and maintain our competi- tive position. Our success will depend in part on our ability to obtain patent protection for our products and processes, to preserve our copyrights and trade secrets, to operate without infringing the proprietary rights of third parties and to acquire licenses related to enabling technology or products used with our BeadArray, DASL, GoldenGate, Sentrix and Oligator technologies. We are party to various exclusive and non-exclusive license agreements with third parties, which grant us rights to use key aspects of our array technology, assay methods, chemical detection methods, reagent kits and scanning equipment. We have exclusive licenses from Tufts University to patents that cover our use of BeadArray technology. These patents were ﬁled by Dr. David Walt, a member of our board of directors, the Chairman of our Scientiﬁc Advisory Board and one of our founders. Our exclusive licenses expire with the termination of the underlying patents, which will occur between 2010 and 2020. In 2001, we entered into a non-exclusive license agreement with Amersham Biosciences that covers certain technology contained in our BeadArray Reader. In 2002, we obtained a non-exclusive license from Dade Behring Marburg GmbH that relates to certain components of our GoldenGate assay. We also have additional nonexclusive licenses from various third parties for other components of our products. In all cases, the agreements remain in effect over the term of the underlying patents, may be terminated at our request without further obligation and require that we pay customary royalties while the agreement is in effect. Marketing and Distribution Our current products address the genetic analysis portion of the life sciences market, in particular, experiments involving SNP genotyping and gene expression proﬁling. These experiments may be involved in many areas of biologic research including basic human disease research, pharmaceutical drug discovery and development, pharmacogenomics, toxicogenomics and agricultural research. Our potential customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies, as well as academic or private research centers. The genetic analysis market is relatively new and emerging and its size and speed of development will be ultimately driven by, among other items: ) the ability of the research community to extract medically valuable information from genomics and to apply that knowledge to multiple areas of disease-related research and treatment, ) the availability of sufﬁciently low cost, high-throughput research tools to enable the large amount of experimentation required to study genetic variation and function, and ) the availability of government and private industry funding to perform the research required to extract medically relevant information from genomic analysis. 12 We market and distribute our products directly to customers in North America, major European markets, Japan and Singapore. In each of these areas we have dedicated sales, service and application support personnel responsible for expanding and managing their respective customer bases. In markets outside of these areas, primarily the Paciﬁc Rim countries, we sell our products and provide services to customers through distributors that specialize in life science products. We expect to signiﬁcantly increase our sales and distribution resources during 2005 and beyond as we launch a number of new products and expand the number of customers that can use our products. In late 2004, we entered into a strategic collaboration with Invitrogen Corporation with a goal of leveraging our strength in oligo synthesis with Invitrogen’s extensive sales, marketing and distribution channels. We expect to transition all responsibility for oligo sales, marketing and technical support to Invitrogen in 2005. Manufacturing We manufacture our array platforms, reagent kits, scanning equipment and oligonucleotides in- house and believe that we currently have the ability to manufacture these in sufﬁcient quantity to meet anticipated internal and external needs. We currently depend upon outside suppliers for materials used in the manufacture of our products. We intend to continue, and may extend, the outsourcing of portions of our manufacturing process to subcontractors where we determine it is in our best commercial interests. During 2001, we moved into a new facility which allowed us to design the manufacturing areas to ﬁt our speciﬁc processes, and optimize material ﬂow and personnel movement. In addition, we have implemented information management systems for many of our manufacturing and services operations to manage all aspects of material and sample use. We adhere to access and safety standards required by federal, state and local health ordinances, such as standards for the use, handling and disposal of hazardous substances. Competition Although we expect that our BeadArray products and services will provide signiﬁcant advantages over currently available products and services, we expect to encounter intense competition from other companies that offer products and services for the SNP genotyping and gene expression markets. These include companies such as Aclara Biosciences (recently acquired by ViroLogic), Affymetrix, Agilent, Amersham Biosciences (recently acquired by GE Corp.), Applied Biosystems, Beckman Coulter, Caliper Technologies, Luminex, ParAllele Bioscience, Perlegen Sciences, Sequenom and Third Wave Technologies. Many of these companies have or will have substantially greater ﬁnancial, technical, research, and other resources and larger, more established marketing, sales, distribution and service organizations than we do. In addition, they may have greater name recognition than we do in the markets we need to address and in some cases a large installed base of systems. Each of these markets is very competitive and we expect new competitors to emerge and the intensity of competition to increase in the future. In order to effectively compete with these companies, we will need to demonstrate that our products have superior throughput, cost and accuracy advantages over the existing products. Rapid technological development may result in our products or technologies becoming obsolete. Products offered by us could be made obsolete either by less expensive or more effective products based on similar or other technologies. Although we believe that our technology and products will offer advantages that will enable us to compete effectively with these companies, we cannot assure you that we will be successful. Segment and Geographic Information We operate in one business segment, for the development, manufacture and commercialization of tools for genetic analysis. Our operations are treated as one segment as we only report operating results on an aggregate basis to chief operating decision makers of Illumina. 13 During 2004, $26.4 million, or 52%, of our total revenues came from customers outside the United States, as compared to $14.4 million, or 51%, in 2003. We expect that sales to international customers will continue to be an important and growing source of revenues. We have sales support resources in Western Europe and direct sales ofﬁces in Japan and Singapore. In addition, we have distributor relationships in various countries in the Paciﬁc Rim region. Information about the geographies in which we operate can be found in the Notes to Consoli- dated Financial Statements at Note 11, ‘‘Segment Information, Geographic Data and Signiﬁcant Customers.’’ Seasonality Historically, customer purchasing patterns have not shown signiﬁcant seasonal variation, although demand for our products is usually lowest in the ﬁrst quarter of the calendar year and highest in the fourth quarter of the calendar year as customers spend unused budget allocations before the end of the year. Environmental Matters We are dedicated to the protection of our employees and the environment. Our operations require the use of hazardous materials which subject us to a variety of federal, state and local environmental and safety laws and regulations. We believe we are in material compliance with current applicable laws and regulations; however, we could be held liable for damages and ﬁnes should contamination of the environment or individual exposures to hazardous substances occur. In addition, we cannot predict how changes in these laws and regulations, or the development of new laws and regulations, will affect our business operations or the cost of compliance. Employees As of January 2, 2005, we had a total of 278 employees, 60 of whom hold Ph.D. degrees and 37 of such Ph.D. degreed employees are engaged in full-time research and development activities. None of our employees is represented by a labor union. We consider our employee relations to be positive. Executive Ofﬁcers Age Position Our executive ofﬁcers as of February 28, 2005, are as follows: Name Jay T. Flatley ******************* David L. Barker, Ph.D. ********** Paulette D. Cabral ************** David C. Douglas *************** Noemi C. Espinosa ************* Robert C. Kain ***************** Timothy M. Kish **************** Arnold Oliphant, Ph. D ********** Tristan B. Orpin***************** John R. Stuelpnagel, DVM ******* President, Chief Executive Ofﬁcer and Director Vice President, Chief Scientiﬁc Ofﬁcer Vice President of Human Resources Vice President of Manufacturing Vice President of Intellectual Property Vice President of Engineering Vice President, Chief Financial Ofﬁcer Vice President of Scientiﬁc Operations Vice President of Worldwide Sales Founder, Senior Vice President, Chief Operating Ofﬁcer and Director 52 63 60 50 46 44 53 45 39 47 14 Jay T. Flatley has served as our President, Chief Executive Ofﬁcer and a Director since October 1999. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Ofﬁcer and a Director of Molecular Dynamics, a life sciences company, from May 1994 to September 1999. He served in various other positions with that company from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director at GenVault. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University. David L. Barker, Ph.D., has served as our Vice President and Chief Scientiﬁc Ofﬁcer since March 2000. Prior to joining us, Dr. Barker was Vice President and Chief Science Advisor at Amersham Pharmacia Biotech, a life sciences company, from September 1998 to March 2000. From May 1997 to September 1998, Dr. Barker was Vice President of Research and Business Development at Molecular Dynamics. From 1992 to 1997, he was Vice President of Scientiﬁc Development. From 1988 to 1995, he held various other positions with that company. Dr. Barker holds a B.S. in Chemistry from California Institute of Technology and received his Ph.D. in Biochemistry from Brandeis University. Paulette D. Cabral has served as our Vice President of Human Resources since March 2001. Prior to joining us, Ms. Cabral was the Vice President of Human Resources at Marimba, Inc., an internet infrastructure company, from July 2000 to February 2001. From December 1996 to July 2000, Ms. Cabral held various human resource positions at Molecular Dynamics; from 1999 to 2000, she was Vice President of Human Resources. Previous to that she held various positions at Acuson Corporation and Spectra Physics. Ms. Cabral holds a B.A. in Sociology from San Jose State University. David C. Douglas has served as our Vice President of Manufacturing since January 2001. Prior to joining us, Mr. Douglas was Vice President of Operations at POSDATA Inc., an information technology equipment company, from July 1989 to December 2000. From July 1988 to July 1989, Mr. Douglas was Test Operations Manager at Acuson Computed Sonography, a medical equipment company. Previous to that he held various positions at Plexus Computers and Spectra Physics. Mr. Douglas holds a B.S. in Electronics Engineering Technology from Oregon Institute of Technology. Noemi C. Espinosa has served as our Vice President of Intellectual Property since May 2000 and our Corporate Secretary since January 2001. Prior to joining us, Ms. Espinosa was a partner with the ﬁrm of Brobeck, Phleger & Harrison LLP from January 1992 to April 2000, having joined the ﬁrm in 1990. From 1983 to 1990, Ms. Espinosa was associated with the intellectual property ﬁrm of Townsend & Townsend. Ms. Espinosa holds a B.S. in Chemical Engineering from San Jose State University and a J.D. from the University of California, Hastings College of Law. She is registered to practice before the United States Patent and Trademark Ofﬁce. Robert C. Kain has served as our Vice President of Engineering since December 1999. Prior to joining us, Mr. Kain was Senior Director of Engineering at Molecular Devices from July 1999 to December 1999. Previously, Mr. Kain served as Director of Microarray Engineering at Molecular Dynamics from August 1998 to July 1999 and in other positions from August 1996 to August 1998. From 1983 to 1988, Mr. Kain was employed at DatagraphiX, an information technology equipment company. Mr. Kain received his B.S. in Physics from San Diego State University and his M.B.A. from St. Mary’s College. Timothy M. Kish has served as our Vice President and Chief Financial Ofﬁcer since May 2000. Prior to joining us, Mr. Kish was Vice President, Finance and Chief Financial Ofﬁcer at Biogen, Inc., a biopharmaceutical company, from September 1993 to April 2000. He served as Corporate Controller of that company from 1986 to 1993. From 1983 to 1986, Mr. Kish was Director of Finance at Allied Health & Scientiﬁc Products Company, a subsidiary of Allied-Signal Corporation. Mr. Kish holds a B.B.A. from Michigan State University and an M.B.A. from the University of Minnesota. 15 Arnold Oliphant, Ph.D., has served as our Vice President of Scientiﬁc Operations since October 2000. Prior to joining us, Dr. Oliphant was Vice President of Functional Genomics at Myriad Genetics, a genomics company, from 1997 to September 2000 and was Process Development and Production Director from January 1995 to June 1997. From January 1992 to January 1995, Dr. Oliphant held several positions at Pioneer Hybrid International, a plant genetics company and prior to that was an Assistant Professor at the University of Utah. Dr. Oliphant received his B.A. in biology from the University of Utah and his Ph.D. in Genetics from the Harvard Medical School. Tristan Orpin has served as our Vice President of Worldwide Sales since December 2002. Prior to joining us, Mr. Orpin was the Vice President of Sales and Marketing at Sequenom, a genomics company, from August 2001 to November 2002 and was Director of Sales and Marketing from September 1999 to August 2001. From December 1988 to September 1999, Mr. Orpin served in several senior sales and marketing positions at Bio-Rad Laboratories, a life sciences company. Mr. Orpin received his BSc. in Biochemistry from the University of Melbourne. John R. Stuelpnagel, D.V.M., one of our founders, is our Senior Vice President and Chief Operating Ofﬁcer and has been a director since April 1998. From October 1999 to April 2002, he served as our Vice President of Business Development. From April 1998 to October 1999, he served as our acting President and Chief Executive Ofﬁcer and was acting Chief Financial Ofﬁcer through April 2000. While founding Illumina, Dr. Stuelpnagel was an associate with CW Group, a venture capital ﬁrm, from June 1997 to September 1998 and with Catalyst Partners, a venture capital ﬁrm, from August 1996 to June 1997. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles. Item 2. Properties. Our principal research and development, manufacturing and administrative facilities occupy approximately 90,000 square feet of three buildings located in San Diego, California, which we purchased, along with eight acres of adjacent land, in January 2002. In connection with this purchase we assumed a $26 million, 10-year mortgage on the property at a ﬁxed interest rate of 8.36%. In June 2004, we entered into a conditional agreement to sell our land and buildings for $42.0 million and to lease back such property for an initial term of ten years. The sale was completed in August 2004, at which time the lease was signed. We expect that these facilities will be sufﬁcient for our San Diego based operations for the foreseeable future. In February 2003, the Company began leasing approximately 3,300 square feet of ofﬁce space in Tokyo and in January 2004, began leasing approximately 1,600 square feet of ofﬁce space in Singapore. These facilities are used by local sales, marketing and ﬁeld service personnel. Item 3. Legal Proceedings. Termination-of-Employment Lawsuit In March 2001, a complaint seeking damages of an unspeciﬁed amount was ﬁled against us by a former employee in the Superior Court of the State of California in connection with the employee’s termination of employment with Illumina. In July 2002 a California Superior Court judgment was rendered against the Company and we recorded a $7.7 million charge in our ﬁnancial results for the second quarter of 2002 to cover total damages and remaining expenses. We appealed the decision, and in December 2004, the Fourth Appellate District Court of Appeal, in San Diego, California, reduced the amount of the award. We recorded interest expense on the $7.7 million during the appeal based on the statutory rate. As a result of the revised judgment, we reduced the $9.2 million liability on our balance sheet to $5.9 million and recorded a gain of $3.3 million as a litigation judgment in the fourth quarter of 2004. 16 Litigation with Applera Corporation’s Applied Biosystems Group In December 2002, Applied Biosystems initiated a patent infringement suit and sought to compel arbitration of an alleged breach of the joint development agreement. In December 2002, we ﬁled a suit alleging breach of contract, breach of the implied covenant of good faith and fair dealing, unfair competition and other allegations against Applied Biosystems in San Diego Superior Court, and moved to prevent the arbitration of our joint development agreement sought by Applied Biosystems. In January 2004, we notiﬁed Applied Biosystems that we were terminating the joint development agreement. In August 2004, we and Applera entered into a settlement and cross-license agreement. Under the terms of the agreement, we paid Applera a one-time payment of $8.5 million. The settlement agreement also provided for an exchange of royalty-free cross-licenses to certain intellectual property rights, termination of the joint development agreement, dismissal of the federal patent infringement action brought by Applied Biosystems, termination of the arbitration proceeding, and dismissal of our state court action against Applied Biosystems. Our ﬁnancial statements included a $10.0 million advance payment from Applied Biosystems that would have been deducted from the proﬁts otherwise payable to us from Applied Biosystems. As a result of the settlement agreement, we removed this $10.0 million liability from our balance sheet, made a payment of $8.5 million to Applera and recorded a gain of $1.5 million as a litigation settlement. Affymetrix Litigation In July 2004, Affymetrix ﬁled a complaint in the U.S. District Court for the District of Delaware alleging that certain of our products infringe six Affymetrix patents. The suit seeks an unspeciﬁed amount of monetary damages and a judgment enjoining the sale of products, if any, that are determined to be infringing these patents. In September 2004, we ﬁled our answer and counterclaims to Affymetrix’ complaint, seeking declaratory judgments from the court that we do not infringe the Affymetrix patents and that such patents are invalid, and ﬁled counterclaims against Affymetrix for unfair competition and interference with actual and prospective economic advantage. We believe we have meritorious defenses against each of the infringement claims alleged by Affymetrix and intend to vigorously defend ourselves against this suit. However, we cannot be sure we will prevail in this matter. Any unfavorable determination, and in particular, any signiﬁcant cash amounts required to be paid by us or prohibition of the sale of our products and services, could result in a material adverse effect on our business, ﬁnancial condition and results of operations. While the parties have pending motions before the court, no trial date has yet been set for this case. 17 Item 4. Submission of Matters to a Vote of Security Holders. No matters were submitted to a vote of security holders during the fourth quarter of 2004. PART II Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Our common stock has been quoted on the Nasdaq National Market under the symbol ‘‘ILMN’’ since July 28, 2000. Prior to that time, there was no public market for our common stock. The following table sets forth, for the periods indicated, the quarterly high and low sales prices per share of the common stock as reported on the Nasdaq National Market. Our present policy is to retain earnings, if any, to ﬁnance future growth. We have never paid cash dividends and have no present intention to pay cash dividends in the foreseeable future. High First Quarter ******************************************************** $4.01 Second Quarter ***************************************************** 4.25 Third Quarter ******************************************************* 6.00 Fourth Quarter ****************************************************** 9.00 Low $1.71 1.75 2.72 5.09 2003 2004 High Low First Quarter ******************************************************* $10.24 Second Quarter **************************************************** 8.88 Third Quarter ****************************************************** 7.22 Fourth Quarter ***************************************************** 9.65 $6.50 6.07 4.23 6.16 At January 31, 2005, there were approximately 156 stockholders of record and the closing price per share of our common stock, as reported on the Nasdaq National Market on such date, was $9.69. Sales of Unregistered Securities None. Issuer Purchases of Equity Securities We currently have no plans or programs to repurchase shares of our stock. However, in September 2004, we repurchased shares of unvested stock in connection with the termination of an employee as set forth below. Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs 44,428 $0.28 N/A N/A Period September 1 to September 30, 2004****** 18 Use of Proceeds On July 27, 2000, we commenced our initial public offering pursuant to a Registration Statement on Form S-1 (File No. 333-33922) resulting in net offering proceeds of $101.3 million. We will continue to use proceeds from our initial public offering to fund operations. Through January 2, 2005, we have used approximately $19.5 million to purchase property, plant and equipment and approximately $44.4 million to fund general operating expenses. The remaining balance is invested in a variety of interest-bearing instruments including U.S. Treasury securities, corporate debt securities and money market accounts. 19 Item 6. Selected Financial Data. The following selected historical consolidated ﬁnancial data have been derived from our audited consolidated ﬁnancial statements. The balance sheet data as of January 2, 2005 and December 28, 2003 and statements of operations data for each of the three years in the period ended January 2, 2005 are derived from audited consolidated ﬁnancial statements included in this Form 10-K. The balance sheet data as of December 29, 2002, December 30, 2001 and December 31, 2000 and statements of operations data for each of the two years in the period ended December 30, 2001 are derived from our audited consolidated ﬁnancial statements that are not included in this report. You should read this table in conjunction with Item 7, ‘‘Management’s Discussion and Analysis of Financial Condition and Results of Operations,’’ and Item 8, ‘‘Financial Statements and Supplementary Data.’’ Statements of Operations Data Revenue: Product revenue******* Service revenue ******* Research revenue ***** Total revenue ******* Costs and expenses: Cost of product revenue Cost of service revenue ** Research and development ********* Selling, general and administrative ********* Amortization of deferred compensation and other non-cash compensation charges Litigation judgment (settlement), net***** Total costs and expenses ********* Loss from operations ****** Interest income *********** Interest and other expense Net loss... **************** Net loss per share, basic and diluted ************* Shares used in calculating net loss per share, basic and diluted ************* Year Ended January 2, 2005 $40,497 8,075 2,011 50,583 11,572 1,687 Year Ended December 28, 2003 Year Ended December 30, 2001 (In thousands, except per share data) Year Ended December 29, 2002 Year Ended December 31, 2000 $ 18,378 6,496 3,161 28,035 7,437 2,600 $ 4,103 3,305 2,632 10,040 1,815 1,721 $ 897 99 1,490 2,486 489 68 $ 42 — 1,267 1,309 — — 21,114 22,511 26,848 20,735 13,554 25,080 18,899 9,099 5,663 4,193 844 2,454 (4,201) 756 56,096 (5,513) 941 (1,653) 54,657 (26,622) 1,821 (2,262) 4,360 8,052 51,895 (41,855) 3,805 (2,281) 5,850 6,797 — — 32,805 (30,319) 6,198 (702) 24,544 (23,235) 4,722 (93) $ (6,225) $(27,063) $(40,331) $(24,823) $(18,606) $ (0.17) $ (0.85) $ (1.31) $ (0.83) $ (1.37) 35,845 31,925 30,890 29,748 13,557 20 Balance Sheet Data January 2, 2005 December 28, 2003 December 29, 2002 December 30, 2001 December 31, 2000 (In thousands) Cash, cash equivalents and current restricted cash and investments ******** $ 66,994 64,643 94,907 — (123,712) 72,262 Working capital *********** Total assets *************** Long-term debt obligations Accumulated deﬁcit ******* Total stockholders’ equity ** $ 32,882 32,229 99,234 24,999 (117,487) 47,388 $66,294 58,522 121,906 25,620 (90,424) 71,744 $93,786 91,452 122,465 590 (50,093) 106,791 $118,719 126,260 132,793 887 (25,270) 124,100 See Note 1 of Notes to Consolidated Financial Statements for an explanation of the determination of the number of shares used to compute basic and diluted net loss per share. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation. The following discussion and analysis should be read with ‘‘Selected Financial Data’’ and our consolidated ﬁnancial statements and notes thereto included elsewhere in this Annual Report on Form 10-K. The discussion and analysis in this Annual Report on Form 10-K may contain forward- looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. The cautionary statements made in this Annual Report on Form 10-K should be read as applying to all related forward-looking statements wherever they appear in this Annual Report on Form 10-K. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to these differences include those discussed in ‘‘Factors Affecting Operating Results’’ below as well as those discussed elsewhere. Overview Illumina, Inc. was incorporated in April 1998. We develop and market next-generation tools for the large-scale analysis of genetic variation and function. Understanding genetic variation and function is critical to the development of personalized medicine, a key goal of genomics. Using our technologies, we have developed a comprehensive line of products that are designed to provide the throughput, cost effectiveness and ﬂexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. This information is expected to correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more speciﬁcally, and permitting better choices of drugs for individual patients. In 2001, we began commercial sale of short pieces of DNA, or oligos, manufactured using our proprietary Oligator technology. We believe our Oligator technology is more cost effective than competing technologies, which has allowed us to market our oligonucleotides under a price leadership strategy while still achieving attractive gross margins. In 2001, we also initiated our SNP genotyping services product line. As a result of the increasing market acceptance of our high throughput, low cost BeadArray technology, we have entered into genotyping services contracts with many leading genotyping centers, and have been awarded $9.1 million from the National Institutes of Health to play a major role in the ﬁrst phase of the International HapMap Project. 21 Our production-scale BeadLab is based on the system we developed that has been operational in our genotyping service product line since 2001. In addition to our Sentrix Array Matrices, it includes the BeadArray Reader, a proprietary scanner that uses a laser to read the results of experiments captured on our arrays, as well as the GoldenGate SNP genotyping assay which can analyze up to 1536 SNPs per DNA sample. This system is being marketed to a small number of high throughput genotyping users. As of January 2, 2005, we have installed and recorded revenue for nine BeadLabs. In 2003, we announced the launch of several new products, including 1) a new array format, the Sentrix BeadChip, which signiﬁcantly expands market opportunities for our BeadArray technology and provides increased experimental ﬂexibility for life science researchers; 2) a gene expression product line on both the Sentrix Array Matrix and the Sentrix BeadChip that allows researchers to analyze a focused set of genes across eight to 96 samples on a single array; and 3) a benchtop SNP genotyping and gene expression system, the BeadStation, for performing moderate-scale genotyping and gene expression using our technology. The BeadStation includes our BeadArray Reader, analysis software and assay reagents and is designed to match the throughput requirements and variable automation needs of individual research groups and core labs. Sales of these products began in the ﬁrst quarter of 2004 and, as of January 2, 2005, we have shipped 42 BeadStations. In 2004, we announced the launch of new Sentrix BeadChips for whole-genome gene expression and whole-genome genotyping. The whole-genome gene expression BeadChips are designed to enable high-performance, cost-effective, whole-genome expression proﬁling of multiple samples on a single chip, resulting in a dramatic reduction in cost of whole-genome expression analysis while allowing researchers to expand the scale and reproducibility of large-scale biological experimentation. The whole-genome genotyping BeadChip can be scaled to unlimited levels of multiplexing without compromising data quality and will provide scientists the ability to query hundreds of thousands of SNPs in parallel. In 2004, we also announced two new versions of the Sentrix Array Matrix designed for researchers who want to take advantage of our technology, but whose projects require fewer SNPs per sample than the number utilized on our standard 1536-plex array products. In late 2004, we announced a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. Under the agreement, we intend to expand our Oligator DNA synthesis technology to include both plate and tube based capability and Invitrogen will be responsible for sales, marketing and technical support. Proﬁts from sales of collaboration products will be divided equally between the two companies. In early 2005, we expanded our gene expression portfolio by announcing the launch of a new assay, DASL, for generating gene expression proﬁles from RNA samples including those containing partially degraded RNAs. We also announced a standard DASL cancer panel. Prior to our DASL assay, degraded RNA samples have been reliably assayed only with expensive, low-multiplex approaches. In February 2005, we signed a deﬁnitive agreement and plan of merger with CyVera Corporation, a privately-held Connecticut-based company, pursuant to which CyVera will become a wholly-owned subsidiary of Illumina. CyVera’s digital-microbead platform is highly complementary to our portfolio of products and services and upon closing of the transaction, will become an integral part of our BeadArray technology. The acquisition is expected to provide us with a comprehensive approach to bead-based assays for biomarker R&D and in-vitro and molecular diagnostic opportunities, including those that require low-complexity as well as high-complexity testing. The aggregate consideration for the transaction is $17.5 million, consisting of approximately 1.5 million shares of Illumina common stock and the payment of approximately $2.3 million of CyVera’s liabilities at the closing. The closing is subject to customary closing conditions and is expected to occur by the end of March 2005. We expect the ﬁrst products based on CyVera’s technology to be available in the second half in 2006. We are seeking to expand our customer base for our BeadArray technology; however, we can give no assurance that our sales efforts will continue to be successful. 22 Our revenues are subject to ﬂuctuations due to the timing of sales of high-value products and service projects, the impact of seasonal spending patterns, the timing and amount of government grant funding programs, the timing and size of research projects our customers perform, changes in overall spending levels in the life science industry and other unpredictable factors that may affect our customer ordering patterns. Approximately 30% of our revenues for the year 2004 resulted from transactions that were funded under the International HapMap Project. We currently expect that most of the activities under this grant involving the Company and its customers will be completed in early 2005. We expect that the planned commercial launch of our whole genome genotyping and gene expression arrays, combined with the continued expansion of our existing product lines, will offset the loss of revenues funded by the HapMap grant and will drive future revenue growth. However, any signiﬁcant delays in the commercial launch of these new products, unfavorable sales trends in our existing product lines, or impacts from the other factors mentioned above, could adversely affect our revenue growth in 2005 or cause a sequential decline in quarterly revenues. Due to the possibility of ﬂuctuations in our revenue and net income or loss, we believe quarterly comparisons of our operating results are not a good indication of our future performance. We have incurred substantial operating losses since our inception. As of January 2, 2005, our accumulated deﬁcit was $123.7 million, and total stockholders’ equity was $72.3 million. These losses have principally occurred as a result of the substantial resources required for the research, develop- ment and manufacturing scale up effort required to commercialize our products and services, as well as charges of $5.9 million related to a termination-of-employment lawsuit. We expect to continue to incur substantial costs for research, development and manufacturing scale up activities over the next several years. We will also need to signiﬁcantly increase our selling, general and administrative costs as we build up our sales and marketing infrastructure to expand and support the sale of systems, other products and services. As a result of the expected increase in expenses, we will need to increase revenue signiﬁcantly to achieve proﬁtability. Critical Accounting Estimates General Our discussion and analysis of our ﬁnancial condition and results of operations is based upon our consolidated ﬁnancial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of ﬁnancial statements requires that management make estimates, assumptions and judgments with respect to the application of account- ing policies that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. Actual results could differ from those estimates. Our signiﬁcant accounting policies are described in Note 1 to our consolidated ﬁnancial state- ments. Certain accounting policies are deemed critical if 1) they require an accounting estimate to be made based on assumptions that were highly uncertain at the time the estimate was made, and 2) changes in the estimate that are reasonably likely to occur, or different estimates that we reasonably could have used, would have a material effect on our consolidated ﬁnancial statements. Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors, and the Audit Committee has reviewed the disclosure. In addition, there are other items within our ﬁnancial statements that require estimation, but are not deemed critical as deﬁned above. We believe the following critical accounting policies reﬂect our more signiﬁcant estimates and assumptions used in the preparation of the consolidated ﬁnancial statements. 23 Revenue Recognition Our sales are primarily from two sources: product revenue and services revenue. Product revenue consists of sales of oligonucleotides, arrays, assay reagents, genotyping systems and gene expression systems. Services revenue consists of revenue received for performing genotyping services and extended warranty sales. As described below, signiﬁcant judgments and estimates must be made and used in connection with the revenue recognized in any accounting period. We recognize revenue in accordance with the guidelines established by SEC Staff Accounting Bulletin (SAB) No. 104. Under SAB 104, revenue cannot be recorded until all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller’s price to the buyer is ﬁxed or determinable; and collectibility is reasonably assured. Product delivery generally occurs when product is delivered to a common carrier or when the customer receives the product, depending on the nature of the arrangement and provided no signiﬁcant obligations remain. BeadLabs are considered delivered upon shipment, installation, training and fulﬁllment of contractually deﬁned acceptance criteria and we need to determine the completion of each of these deliverables before revenue can be recognized. Genotyping services are considered delivered generally at the time the genotyping data is delivered to the customer. We have been awarded $9.1 million from the National Institutes of Health to perform genotyping services in connection with the ﬁrst phase of the International HapMap Project. A portion of the services related to this project is considered delivered at the time the related costs are incurred while the remainder is considered delivered upon the delivery of genotyping data. In order to assess whether the price is ﬁxed and determinable, we ensure there are no refund rights. If payment terms are based on future performance, we defer revenue recognition until the price becomes ﬁxed and determinable. We assess collectibility based on a number of factors, including past transaction history with the customer and the creditworthiness of the customer. If we determine that collection of a payment is not reasonably assured, we defer revenue recognition until the time collection becomes reasonably assured, which is generally upon receipt of payment. Changes in judgments and estimates made in determining whether the criteria of SAB 104 have been met might result in a change in the timing or amount of revenue recognized. Sales of our genotyping and gene expression systems include a standard one year warranty. We also sell separately priced maintenance (extended warranty) contracts, which are generally for one or two years, upon the expiration of the initial warranty. Revenue for extended warranty sales is recognized ratably over the term of the extended warranty. Reserves are provided for estimated product warranty expenses at the time the associated revenue is recognized. If we were to experience an increase in warranty claims or if costs of servicing our warrantied products were greater than our estimates, our gross margins could be adversely affected. While the majority of our sales agreements contain standard terms and conditions, we do enter into agreements that contain multiple elements or non-standard terms and conditions. Emerging Issues Task Force No. 00-21 (‘‘EITF 00-21’’), ‘‘Revenue Arrangements with Multiple Deliverables’’, provides guidance on accounting for arrangements that involve the delivery or performance of multiple products, services, or rights to use assets within contractually binding arrangements. Signiﬁ- cant contract interpretation is sometimes required to determine the appropriate accounting, including whether the deliverables speciﬁed in a multiple element arrangement should be treated as separate units of accounting for revenue recognition purposes, and if so, how the price should be allocated among the deliverable elements, when to recognize revenue for each element, and the period over which revenue should be recognized. We recognize revenue for delivered elements only when we believe the fair values of undelivered elements are known and there are no uncertainties regarding customer acceptance. 24 A third source of revenue, research revenue, consists of amounts earned under research agree- ments with government grants, which is recognized in the period during which the related costs are incurred. All revenues are recorded net of any applicable allowances for returns or discounts. Allowance for Doubtful Accounts We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We evaluate the collectibility of our accounts receivable based on a combination of factors. We regularly analyze customer accounts, review the length of time receivables are outstanding and review historical loss rates. If the ﬁnancial condition of our customers were to deteriorate, additional allowances could be required. Inventory Valuation We record adjustments to inventory for potentially excess, obsolete or impaired goods in order to state inventory at net realizable value. We must make assumptions about future demand, market conditions and the release of new products that will supercede old ones. We regularly review inventory for excess and obsolete products and components, taking into account product life cycle and development plans, product expiration and quality issues, historical experience and our current inventory levels. If actual market conditions are less favorable than anticipated, additional inventory adjustments could be required. Contingencies We are subject to legal proceedings primarily related to intellectual property matters. Based on the information available at the balance sheet dates and through consultation with our legal counsel, we assess the likelihood of any adverse judgments or outcomes of these matters, as well as the potential ranges of probable losses. If losses are probable and reasonably estimable, we will record a reserve in accordance with Statement of Financial Accounting Standards No. 5, ‘‘Accounting for Contingencies’’. Currently we have no such reserves recorded. Any reserves recorded in the future may change due to new developments in each matter. Recently Issued Accounting Standards In December 2004, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 123 (revised 2004), Share Based Payment (SFAS 123R), which is a revision of FASB Statement No. 123, Accounting for Stock-Based Compensation (SFAS 123). This statement supercedes APB Opinion 25, Accounting for Stock Issued to Employees (APB 25), and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach in SFAS 123R is similar to the approach described in SFAS 123; however, SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. We currently utilize the Black-Scholes model to measure the fair value of stock options granted to employees under the pro forma disclosure requirements of FAS 123. While SFAS 123R permits companies to continue to use such model, it also permits the use of a ‘‘lattice’’ model. We have not yet determined which model we will use to measure the fair value of employee stock options under the adoption for SFAS 123R. The new standard is effective for periods beginning after June 15, 2005, and we expect to adopt SFAS 123R on July 4, 2005. 25 We currently account for share-based payments to employees using APB 25’s intrinsic value method and, as such, recognize no compensation cost for employee stock options granted with exercise prices equal to or greater than the fair value of our common stock on the date of the grant. Accordingly, the adoption of SFAS 123R’s fair value method is expected to result in signiﬁcant non- cash charges which will increase our reported operating expenses; however, it will have no impact on our cash ﬂows. The impact of adoption of SFAS 123R cannot be predicted at this time because it will depend on the level of share-based payments granted in the future and the model we choose to use. However, had we adopted SFAS 123R in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net loss under Stock- Based Compensation in Note 1 to our consolidated ﬁnancial statements. Results of Operations To enhance comparability, the following table sets forth audited Consolidated Statements of Operations data for the years ended January 2, 2005, December 28, 2003 and December 29, 2002 stated as a percentage of total revenue. Year Ended January 2, 2005 Year Ended December 28, 2003 Year Ended December 29, 2002 Revenue ************************************* Product revenue **************************** Service revenue **************************** Research revenue *************************** Total revenue***************************** Costs and expenses: Cost of product revenue********************* Cost of service revenue ********************* Research and development ****************** Selling, general and administrative *********** Amortization of deferred compensation and other non-cash compensation charges ****** Litigation judgment (settlement), net********** Total costs and expenses ****************** Loss from operations ************************** Interest income ******************************* Interest and other expense ******************** Net loss ************************************* 80% 16 4 66% 23 11 100 100 23 3 41 50 2 (8) 111 (11) 2 (3) 27 9 80 67 9 3 195 (95) 6 (8) 41% 33 26 100 18 17 267 91 44 80 517 (417) 38 (23) (12)% (97)% (402)% Comparison of Years Ended January 2, 2005 and December 28, 2003 Our ﬁscal year is 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, and September 30. The years ended January 2, 2005 and December 28, 2003 are 53 and 52 weeks, respectively. 26 Revenue Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Product revenue *********************************** Service revenue *********************************** Research revenue ********************************** Total revenue************************************ $40,497 8,075 2,011 $50,583 $18,378 6,496 3,161 $28,035 Change 120% 24 (36) 80% Revenue for the years ended January 2, 2005 and December 28, 2003 was $50.6 million and $28.0 million, respectively. Product revenue increased to $40.5 million in 2004 from $18.4 million in 2003. The increase resulted almost entirely from sales of consumables used on our BeadLabs and BeadStations and sales of our benchtop BeadStations, offset by fewer sales of our production-scale BeadLabs. In 2003, we had no sales of BeadStations and we only began selling consumable products in May 2003. Service revenue increased to $8.1 million in 2004 from $6.5 million in 2003. Substantially all of this increase relates to SNP genotyping services performed for the International HapMap Project. We are the recipient of a grant from the National Institutes of Health covering our participation in the ﬁrst phase of the International HapMap Project, which is a $100 million internationally funded successor project to the Human Genome Project that will help identify a map of genetic variations that may be used to perform disease-related research. We could receive up to $9.1 million of funding for this project which covers basic research activities, the development of SNP assays and the genotyping to be performed on those assays. We have recognized revenue under this grant of $8.4 million and, as of the end of 2004, we had approximately $0.7 million of funding remaining related to this project which is expected to be received in early 2005. Government grants and other research funding decreased to $2.0 million for the year ended January 2, 2005 from $3.2 million for the year ended December 28, 2003 primarily due to a decrease in internal research spending for our grant from the National Institutes of Health covering our participation in the International HapMap Project. We expect government grants to decline as a percentage of total revenues. To expand revenue in the future, we have recently launched a series of new products that we expect to begin selling in 2005. These include a new assay, DASL, for generating gene expression proﬁles from RNA samples including those containing partially degraded RNAs, two multi-sample whole genome gene expression BeadChips and a whole genome genotyping BeadChip. Our BeadLabs address a limited number of potential high throughput genotyping customers, and sales of these systems may decline in 2005 versus 2004. In addition, approximately 30% of our revenues for the year 2004 resulted from transactions that were funded under the International HapMap Project. We expect that most of the activities under this grant involving us and our customers will be completed in early 2005 and that revenue related to this project will decline in 2005 versus 2004. We expect the sales of the new products mentioned above, combined with increased sales of BeadStations and revenue generated from our collaboration with Invitrogen, to offset such declines and for overall revenues to increase above 2004 levels; however, we cannot assure you that we will be successful in these sales efforts. 27 Cost of Product and Service Revenue Cost of product revenue**************************** Cost of service revenue **************************** $11,572 $ 1,687 $7,437 $2,600 Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change 56% (35)% Cost of product and service revenue represents manufacturing costs incurred in the production process, including component materials, assembly labor and overhead, packaging and delivery cost. Costs related to research revenue is included in research and development expense. Cost of product revenue increased to $11.6 million for the year ended January 2, 2005 from $7.4 million for the year ended December 28, 2003. Substantially all of this increase was driven by the sales of our BeadStations and consumables. Gross margin on product revenue increased to 71% in the year ended January 2, 2005, from 60% for the year ended December 28, 2003, due primarily to increased sales of higher margin consumable products, as well as efﬁciencies gained in oligo manufacturing. Cost of service revenue decreased to $1.7 million for the year ended January 2, 2005 from $2.6 million for the year ended December 28, 2003 and gross margin on service revenue increased to 79% in the year ended January 2, 2005, from 60% for the year ended December 28, 2003. This decrease in cost and increase in gross margin is due primarily to efﬁciencies gained in SNP genotyping services, as well as lower costs of oligos used in the genotyping services process. We expect product mix will continue to affect our future gross margins, and any increase in the proportion of consumable sales to total sales will continue to favorably affect our gross margins. However, we expect our market will become increasingly price competitive, and over the longer term, our margins may decline. Research and Development Expenses Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change Research and development ************************* $21,114 $22,511 (6)% Our research and development expenses consist primarily of salaries and other personnel-related expenses, laboratory supplies and other expenses related to the design, development, testing and enhancement of our products. We expense our research and development expenses as they are incurred. Research and development expenses decreased $1.4 million to $21.1 million for the year ended January 2, 2005 from $22.5 million for the year ended December 28, 2003. Approximately $0.9 million of the decrease is attributable to personnel related expenses and related lab supplies and the majority of the remaining $0.5 million is attributable to lower manufacturing-related resources needed to support research efforts and a decrease in depreciation expense. During the year ended January 2, 2005, the cost of BeadArray technology research activities decreased $0.4 million as compared to the year ended December 28, 2003. The decrease is primarily the result of completing the development of several products that were commercially launched in late 2003 and 2004 such as our BeadStation and focused gene set array products. Research to support our Oligator technology platform decreased $1.0 million in the year ended January 2, 2005 as compared to the year ended December 28, 2003. In the second quarter of 2003, we implemented additional Oligator manufacturing and software enhancements to expand capacity, increase throughput, and further reduce operating costs. In addition, as we increase our product sales, a smaller portion of our manufacturing resources are now used to support research efforts as compared to the same periods in 2003. 28 We expect that our research and development expenses will increase in the near term due to the allocation to research and development of rent expense from the new lease on our building and increased spending levels for new product development. In addition, we expect an increase in research and development expenses in connection with our proposed acquisition of CyVera Corporation, which is expected to close in March 2005. Stock based compensation related to research and development employees and consultants was $0.3 million for the year ended January 2, 2005 as compared to $1.3 million for the year ended December 28, 2003. Selling, General and Administrative Expenses Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change Selling, general and administrative ****************** $25,080 $18,899 33% Our selling, general and administrative expenses consist primarily of personnel costs for sales and marketing, ﬁnance, human resources, business development and general management, as well as professional fees, such as expenses for legal and accounting services. Selling, general and administra- tive expenses increased $6.2 million to $25.1 million for the year ended January 2, 2005 from $18.9 million for the year ended December 28, 2003. Approximately $5.2 million of the increase is due to higher sales and marketing costs, of which $4.1 million is attributable to personnel related expenses and $0.7 million is attributable to an increase in facility related expenses. Approximately $1.0 million of the increase in selling, general and administrative expenses is related to general and administrative costs, of which $0.4 million is related to personnel related expenses, and the majority of the remaining $0.6 million is attributable to expenses associated with Sarbanes-Oxley compliance and our interna- tional expansion. We expect that our selling, general and administrative expenses will accelerate as we expand our staff, add sales and marketing infrastructure, incur additional costs to support the commercialization and support of an increasing number of products, and due to the allocation to selling, general and administrative of rent expense from the new lease on our building. Stock based compensation related to selling, general and administrative employees, directors and consultants was $0.5 million for the year ended January 2, 2005 as compared to $1.2 million for the year ended December 28, 2003. Amortization of Deferred Compensation and Other Stock-Based Compensation Charges Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change Amortization of deferred compensation and other stock-based compensation charges **************** $844 $2,454 (66)% From our inception through July 27, 2000, in connection with the grant of certain stock options and sales of restricted stock to employees, founders and directors, we have recorded deferred stock compensation totaling $17.6 million, representing the difference between the exercise or purchase price and the fair value of our common stock as estimated for ﬁnancial reporting purposes on the date such stock options were granted or such restricted stock was sold. We recorded this amount as a component of stockholders’ equity and amortize the amount as a charge to operations over the vesting period of the restricted stock and options. 29 We recognize compensation expense over the vesting period for employees, founders and directors, using an accelerated amortization methodology in accordance with Financial Accounting Standards Board Interpretation No. 28. For consultants, deferred compensation is recorded at the fair value for the options granted or stock sold in accordance with Statement of Financial Accounting Standards No. 123 and is periodically re-measured and expensed in accordance with Emerging Issues Task Force No. 96-18. We recorded amortization of deferred compensation of $0.8 million and $2.5 million for the years ended January 2, 2005 and December 28, 2003, respectively. We expect expenses related to stock based compensation to increase signiﬁcantly beginning in the third quarter of 2005 as we implement the requirements of SFAS 123R. Although the adoption of SFAS 123R’s fair value method is expected to result in a signiﬁcant increase in our reported operating expenses, it will have no impact on our cash ﬂows. SFAS 123R is discussed further in ‘‘Recently Issued Accounting Standards’’ above and Note 1 to our consolidated ﬁnancial statements. Litigation Judgment (Settlement), net Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change Litigation judgment (settlement), net***************** $(4,201) $756 (656)% A $7.7 million charge was recorded in June 2002 to cover total damages and estimated expenses related to a jury verdict in a termination-of-employment lawsuit. We appealed the decision, and in December 2004, the Fourth Appellate District Court of Appeal, in San Diego, California, reduced the amount of the award. During the appeal process, the court required us to incur interest charges on the judgment amount at statutory rates until the case was resolved. For the years ended January 2, 2005 and December 28, 2003 we recorded $0.6 million and $0.8 million, respectively, as litigation expense for such interest charges. As a result of the revised judgment, we reduced the $9.2 million liability on our balance sheet to $5.9 million and recorded a gain of $3.3 million as a litigation judgment in the fourth quarter of 2004. In 1999, we entered into a joint development agreement with Applied Biosystems Group, an operating group of Applera Corporation, under which the companies agreed to jointly develop a SNP genotyping system that would combine our BeadArray technology with Applied Biosystems’ assay chemistry and scanner technology. In conjunction with the agreement, Applied Biosystems agreed to provide us with non-refundable research and development support of $10.0 million, all of which was provided by December 2001. As of December 28, 2003, this amount was recorded on our balance sheet as an advance payment from a former collaborator. In December 2002, Applied Biosystems initiated a patent infringement suit and sought to compel arbitration of an alleged breach of the joint development agreement. We initiated a suit in state court seeking to enjoin the arbitration and alleged that Applied Biosystems had breached the joint development agreement. In August 2004, we entered into a settlement and cross-license agreement with Applera. As a result of the settlement, we removed the $10.0 million liability from our balance sheet, made a payment of $8.5 million to Applera and recorded a gain of $1.5 million as a litigation settlement. Interest Income Interest income ************************************ $941 $1,821 (48%) Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change 30 Interest income on our cash and cash equivalents and investments was $0.9 million and $1.8 million for the years ended January 2, 2005 and December 28, 2003, respectively. The decrease is due to lower effective interest rates, partially offset by higher average cash balances. Interest and Other Expense Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Change Interest and other expense ************************* $1,653 $2,262 (27%) Interest and other expense primarily consists of interest expense, which was $1.4 million and $2.2 million for the years ended January 2, 2005 and December 28, 2003, respectively. Interest expense relates primarily to a $26.0 million ﬁxed rate loan which was paid off in August 2004 in connection with the sale of our San Diego facilities. In the year ended January 2, 2005, we recorded approximately $150,000 in losses due to foreign currency transactions as compared to approximately $5,000 in gains, for the year ended December 28, 2003. Estimated foreign income taxes were approximately $135,000 and $45,000 for the years ended January 2, 2005 and December 28, 2003, respectively. Provision for Income Taxes We incurred net operating losses for the years ended January 2, 2005 and December 28, 2003, and accordingly, we did not pay any U.S. federal or state income taxes. We have recorded a valuation allowance for the full amount of the resulting net deferred tax asset, as the future realization of the tax beneﬁt is uncertain. As of January 2, 2005, we had net operating loss carryforwards for federal and state tax purposes of approximately $86.5 million and $39.1 million, respectively, which begin to expire in 2018, unless previously utilized. We also had U.S. federal and state research and development tax credit carryforwards of approximately $3.1 million and $3.0 million, respectively, which begin to expire in 2018, unless previously utilized. Our utilization of the net operating losses and credits may be subject to substantial annual limitations pursuant to Section 382 and 383 of the Internal Revenue Code, and similar state provisions, as a result of changes in our ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. Comparison of Years Ended December 28, 2003 and December 29, 2002 Revenue Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Product revenue ********************************* Service revenue ********************************* Research revenue ******************************** Total revenue ********************************* $18,378 6,496 3,161 $28,035 $ 4,103 3,305 2,632 $10,040 348% 97 20 179% 31 Revenue for the years ended December 28, 2003 and December 29, 2002 was $28.0 million and $10.0 million, respectively. Product revenue increased to $18.4 million in 2003 from $4.1 million in 2002. The increase resulted almost entirely from the ﬁrst sales of our BeadLab, with six systems sold in the year ended December 28, 2003, along with sales of consumables that are used on these systems. Prior to 2003 we had no sales of BeadLabs or consumable products. SNP genotyping service revenue increased to $6.5 million in 2003 from $3.3 million in 2002. Substantially all of this increase relates to genotyping services performed for the International HapMap Project, which commenced in 2003. Government grants and other research funding increased to $3.2 million for the year ended Decem- ber 28, 2003 from $2.6 million for the year ended December 29, 2002 due to an increase in the number of grants received. Cost of Product and Service Revenue Cost of product revenue ************************* Cost of service revenue ************************** $7,437 $2,600 $1,815 $1,721 Year Ended December 28, 2003 Year Ended December 29, 2002 (In thousands) Change 310% 51% Cost of product revenue increased to $7.4 million the year ended December 28, 2003 from $1.8 million for the year ended December 29, 2002. Substantially all of this increase was driven by the sales of our BeadLabs and consumables, of which we had none in 2002. Gross margin on product revenue increased to 60% in the year ended December 28, 2003, from 56% for the year ended December 29, 2002. This increase is due primarily to increased sales of higher margin products such as array matrices and assay reagents. Cost of service revenue increased to $2.6 million the year ended December 28, 2003 from $1.7 million for the year ended December 29, 2002. Substantially all of this increase was driven by the higher level of SNP genotyping service revenue in 2003 as compared to 2002. Gross margin on service revenue increased to 60% in the year ended December 28, 2003, from 48% for the year ended December 29, 2002 due primarily to efﬁciencies gained in SNP genotyping services. Research and Development Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Research and development *********************** $22,511 $26,848 (16%) Research and development expenses decreased $4.3 million to $22.5 million for the year ended December 28, 2003 from $26.8 million for the year ended December 29, 2002. During the year ended December 28, 2003, the cost of BeadArray technology research activities decreased $3.8 million as compared to the year ended December 29, 2002. The decrease occurred primarily as a result of completing the development of new products launched in 2003. In addition, as we completed development efforts and increased our array-driven product sales, a smaller portion of our manufacturing resources was charged to research and development expense in 2003 than in 2002. Research to support our Oligator technology platform decreased $0.5 million in the year ended December 28, 2003 as compared to the year ended December 29, 2002. This decline is primarily due to higher development expenses incurred in the ﬁrst quarter of 2002 for a major upgrade of our Oligator technology, which resulted in a signiﬁcant increase in our manufacturing capacity. Stock based compensation related to research and development employees and consultants was $1.3 million for the year ended December 28, 2003 as compared to $2.4 million for the year ended December 29, 2002. 32 Selling, General and Administrative Expenses Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Selling, general and administrative **************** $18,899 $9,099 108% Selling, general and administrative expenses increased $9.8 million to $18.9 million for the year ended December 28, 2003 from $9.1 million for the year ended December 29, 2002. Approximately $4.4 million of this increase is related to higher legal expenses, which is primarily due to legal proceedings regarding the disputes with Applied Biosystems. Approximately $4.1 million of the increase is due to higher sales and marketing costs, of which $3.0 million is attributable to personnel related expenses while the majority of the remaining $1.1 million is attributable to an increase in facility related expenses. During 2003, we signiﬁcantly expanded our sales and marketing resources to support the direct sale of our new products, including establishing additional sales operations in Japan and Singapore. Stock based compensation related to selling, general and administrative employees, directors and consultants was $1.2 million for the year ended December 28, 2003 as compared to $2.0 million for the year ended December 29, 2002. Amortization of Deferred Compensation and Other Stock-Based Compensation Charges Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Amortization of deferred compensation and other stock-based compensation charges ************** $2,454 $4,360 (44%) In connection with the grant of stock options and sale of restricted common stock to employees, founders and directors through July 27, 2000, we recorded deferred compensation of approximately $17.6 million. We recorded amortization of this deferred compensation of $2.5 million and $4.4 million for the years ended December 28, 2003 and December 29, 2002, respectively. Litigation Judgment (Settlement), net Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Litigation judgment (settlement), net*************** $756 $8,052 (91%) A $7.7 million charge was recorded in June 2002 to cover total damages and estimated expenses related to a jury verdict in a termination-of-employment lawsuit. We appealed the decision, and in December 2004, the Fourth Appellate District Court of Appeal, in San Diego, California, reduced the amount of the award. During the appeal process, the court required us to incur interest charges on the judgment amount at statutory rates until the case was resolved. For the years ended December 28, 2003 and December 29, 2002, we recorded $0.8 million and $0.4 million, respectively, as litigation expense for such interest charges. Interest Income Interest income********************************** $1,821 $3,805 (52%) Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) 33 Interest income on our cash and cash equivalents and investments was $1.8 million and $3.8 million for the years ended December 28, 2003 and December 29, 2002, respectively. The decrease is due to lower average levels of invested funds and lower effective interest rates. Interest and Other Expense Year Ended December 28, 2003 Year Ended December 29, 2002 Change (In thousands) Interest and other expense *********************** $2,262 $2,281 (1%) Interest expense was $2.2 million and $2.3 million for the years ended December 28, 2003 and December 29, 2002, respectively. Interest expense relates primarily to a $26.0 million ﬁxed rate loan related to the purchase of our new facility during the ﬁrst quarter of 2002. Liquidity and Capital Resources Cashﬂow Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Year Ended December 29, 2002 Net cash used in operating activities************ Net cash provided by (used in) investing activities Net cash provided by ﬁnancing activities ******** Effect of foreign currency translation ************ $(19,574) 57,022 4,875 1 $(18,256) 28,468 216 — $(25,593) (2,641) 26,106 — Net increase (decrease) in cash and cash equivalents********************************* $ 42,324 $ 10,428 $ (2,128) As of January 2, 2005, we had cash, cash equivalents and investments (including restricted cash and investments of $12.2 million) of approximately $67.0 million. We currently invest our funds in U.S. dollar based investment-grade corporate and government debt securities, with strong credit ratings or short maturity mutual funds providing similar ﬁnancial returns. Our operating activities used cash of $19.6 million in the year ended January 2, 2005, as compared to $18.3 million in the year ended December 28, 2003. Net cash used in operating activities in the year ended January 2, 2005 was primarily the result of a net loss from operations of $6.2 million, the payment of an $8.5 million legal settlement, as described under ‘‘Litigation Judgment (Settlement), net’’ above, a $7.2 million increase in accounts receivable due to increased sales and a $2.0 million increase in other assets primarily for the security deposit for the building lease, reduced by non-cash charges of $4.0 million for depreciation and amortization. Net cash used in operating activities in the year ended December 28, 2003 was primarily the result of a net loss from operations of $27.1 million reduced by non-cash charges of $4.5 million for depreciation and amortization and non-cash charges of $2.5 million for amortization of deferred stock compensation. Our investing activities provided cash of $57.0 million in the year ended January 2, 2005 as compared to $28.5 million in the year ended December 28, 2003. Cash provided in investing activities in the year ended January 2, 2005 was due to $40.7 million in proceeds from the sale of our land and buildings, net of fees, and $19.8 million from the sale or maturity of investment securities, net of purchases of investment securities used to provide operating funds for our business, reduced by $3.4 million for the purchase of property and equipment. Cash provided in investing activities in the year ended December 28, 2003 was due primarily to $30.5 million from the sale or maturity of investment securities, net of purchases of investment securities used to provide operating funds for our business, reduced by $2.0 million for the purchase of property and equipment. 34 Our ﬁnancing activities provided $4.9 million in the year ended January 2, 2005 as compared to $0.2 million in the year ended December 28, 2003. Cash provided in ﬁnancing activities in the year ended January 2, 2005 was due primarily to proceeds from the issuance of common stock, including $28.7 million of net proceeds from the sale of approximately 4.6 million shares of our common stock in May 2004, offset by the $25.2 million in long term debt we paid off in connection with the sale of our land and buildings. Cash provided in ﬁnancing activities in the year ended December 28, 2003 was primarily due to proceeds from the issuance of common stock reduced by payments on long-term debt and equipment ﬁnancings. In June 2002, we recorded a $7.7 million charge to cover total damages and estimated expenses related to a termination-of-employment lawsuit. As a result of our decision to appeal the ruling, we ﬁled a surety bond with the court in October 2002 of 1.5 times the judgment amount, or approximately $11.3 million. Under the terms of the bond, we were required to maintain a letter of credit for 90% of the bond amount to secure the bond. Further, we were required to deposit approximately $12.5 mil- lion of marketable securities as collateral for the letter of credit and accordingly, these funds were restricted from use for corporate purposes. A judgment was rendered in December 2004 and a $5.9 million payment was made in early 2005 at which time the restricted funds were released. As of January 2, 2005, we had funding remaining under existing NIH grants of approximately $1.5 million, including $0.7 million available under the International HapMap Project. All of these amounts are expected to be paid in 2005, subject to the actual amount of activities we perform under these grants. Based on our current operating plans, we expect that our current cash and cash equivalents, investments, revenues from sales and funding from grants will be sufﬁcient to fund our anticipated operating needs for at least 24 months. Operating needs include the planned costs to operate our business including amounts required to fund working capital and capital expenditures. At the current time, we have no material commitments for capital expenditures. However, our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our SNP genotyping and gene expression systems and extensions to those products and to expand our oligonucleotide and SNP genotyping services product lines, scientiﬁc progress in our research and development programs, the magnitude of those programs, competing technological and market developments, the successful resolution of our legal proceedings with Affymetrix, the success of our collaboration with Invitrogen and the need to enter into collabora- tions with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. Therefore, we may require additional funding within this 24 month time frame. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, such as an acquisition, even if we believe we have sufﬁcient funds for our current or future operating plans. Further, any additional equity ﬁnancing may be dilutive to our then existing stockholders and may adversely affect their rights. In December, 2003, we ﬁled a shelf registration statement that would allow us to raise up to $65 million of funding through the sale of common stock in one or more transactions. In May 2004, we raised approximately $28.7 million, net of offering expenses, through the sale of our common stock under this shelf registration statement. We currently do not have plans to raise additional funds under this registration statement. Off-Balance Sheet Arrangements and Contractual Obligations We do not participate in any transactions that generate relationships with unconsolidated entities or ﬁnancial partnerships, such as entities often referred to as structured ﬁnance or special purpose entities (‘‘SPEs’’), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of January 2, 2005, we are not involved in any SPE transactions. 35 In January 2002, we purchased two newly constructed buildings and assumed a $26.0 million, 10-year mortgage on the property at a ﬁxed interest rate of 8.36%. In June 2004, we entered into a conditional agreement to sell our land and buildings for $42.0 million and to lease back such property for an initial term of ten years. The sale was completed in August 2004 at which time the lease was signed. After the repayment of the remaining $25.2 million debt and other related transaction expenses, we received $15.5 million in net cash proceeds. We removed the land and net book value of the buildings of $36.9 million from our balance sheet and are recording the resulting $3.7 million gain on the sale of the property over the ten year lease term in accordance with SFAS 13, Accounting for Leases. Under the terms of the lease, we made a $1.9 million security deposit and are paying monthly rent of $318,643 for the ﬁrst year with an annual increase of 3% in each subsequent year. We also lease ofﬁce space under non-cancelable operating leases that expire at various times through January 2007. These leases contain renewal options ranging from 2 to 3 years. As of January 2, 2005, our enforceable and legally binding contractual obligations are (in thousands): Contractual Obligation Operating leases ************* $43,225 Total************************* $43,225 Total Payments Due by Period Less Than 1 Year $4,251 $4,251 1 – 3 Years 3 – 5 Years $8,502 $8,502 $8,576 $8,576 More Than 5 Years $21,896 $21,896 The above table does not include orders for goods and services entered into in the normal course of business that are not enforceable or legally binding. Factors Affecting Our Operating Results Our business is subject to various risks, including those described below. In addition to the other information included in this Form 10-K, the following issues could adversely affect our operating results or our stock price. 36 Litigation or other proceedings or third party claims of intellectual property infringement could require us to spend signiﬁcant time and money and could prevent us from selling our products or services. Our commercial success depends in part on our non-infringement of the patents or proprietary rights of third parties and the ability to protect our own intellectual property. While we recently settled our litigation with Applera Corporation’s Applied Biosystems Group in August 2004, Affymetrix ﬁled a complaint against us in July 2004, alleging infringement of six of its patents, and other third parties have or may assert that we are employing their proprietary technology without authorization. As we enter new markets, we expect that competitors will likely assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. In addition, third parties have or may obtain patents in the future and claim that use of our technologies infringes these patents. We could incur substantial costs and divert the attention of our management and technical personnel in defending ourselves against any of these claims. We may incur the same costs and diversions in enforcing our patents against others. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop, commercialize and sell products, and could result in the award of substantial damages against us. In the event of a successful claim of infringement against us, we may be required to pay damages and obtain one or more licenses from third parties, or be prohibited from selling certain products. We may not be able to obtain these licenses at a reasonable cost, or at all. In that event, we could encounter delays in product introductions while we attempt to develop alternative methods or products. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products, and the prohibition of sale of any of our products could materially affect our ability to grow and to attain proﬁtability. We expect intense competition in our target markets, which could render our products obsolete, result in signiﬁcant price reductions or substantially limit the volume of products that we sell. This would limit our ability to compete and achieve proﬁtability. If we cannot continuously develop and commercialize new products, our revenues may not grow as intended. We compete with life sciences companies that design, manufacture and market instruments for analysis of genetic variation and function and other applications using technologies such as two- dimensional electrophoresis, capillary electrophoresis, mass spectrometry, ﬂow cytometry, microﬂuidics, and mechanically deposited, inkjet and photolithographic arrays. We anticipate that we will face increased competition in the future as existing companies develop new or improved products and as new companies enter the market with new technologies. The markets for our products are characterized by rapidly changing technology, evolving industry standards, changes in customer needs, emerging competition, new product introductions and strong price competition. For example, Affymetrix recently released a 100k SNP genotyping chip and has announced a 500k chip which will compete with our SNP genotyping service and product offerings and several competitors have begun selling a single chip for whole human genome expression which may compete with our gene expression product offerings. One or more of our competitors may render our technology obsolete or uneconomical. Our competitors have greater ﬁnancial and personnel resources, broader product lines, a more established customer base and more experience in research and development than we have. Furthermore, the life sciences and pharmaceutical companies, which are our potential customers and strategic partners, could develop competing products. If we are unable to develop enhancements to our technology and rapidly deploy new product offerings, our business, ﬁnancial condition and results of operations will suffer. 37 We have generated only moderate amounts of revenue from product and service offerings to date. We expect to continue to incur net losses and we may not achieve or maintain proﬁtability. We have incurred net losses since our inception and expect to continue to incur net losses at least through early 2005. At January 2, 2005 our accumulated deﬁcit was approximately $123.7 million, and we incurred a net loss of $6.2 million for the year ended January 2, 2005. The magnitude of our net losses will depend, in part, on the rate of growth, if any, of our revenue and on the level of our expenses. We expect to continue incurring signiﬁcant expenses for research and development, for developing our manufacturing capabilities and for sales and marketing efforts to commercialize our products. In addition, we expect that our selling and marketing expenses will increase at a higher rate in the future as a result of the launch of new products. As a result, we expect that our operating expenses will increase signiﬁcantly as we grow and, consequently, we will need to generate signiﬁcant additional revenue to achieve proﬁtability. Even if we achieve proﬁtability, we may not be able to sustain or increase proﬁtability on a quarterly or annual basis. We have a limited history of commercial sales of systems and consumable products, and our success depends on our ability to develop commercially successful products and on market acceptance of our new and relatively unproven technologies. We may not possess all of the resources, capability and intellectual property necessary to develop and commercialize all the products or services that may result from our technologies. Sales of our genotyping and gene expression systems only began in 2003, and some of our other technologies are in the early stages of commercialization or are still in development. You should evaluate us in light of the uncertainties and complexities affecting similarly situated companies developing tools for the life sciences and pharmaceutical industries. We must conduct a substantial amount of additional research and development before some of our products will be ready for sale and we currently have fewer resources available for research and development activities than many of our competitors. We may not be able to develop or launch new products in a timely manner, or at all, or they may not meet customer requirements or be of sufﬁcient quality or price that enables us to compete effectively in the marketplace. Problems frequently encountered in connection with the development or early commer- cialization of products and services using new and relatively unproven technologies might limit our ability to develop and successfully commercialize these products and services. In addition, we may need to enter into agreements to obtain intellectual property necessary to commercialize some of our products or services. Historically, life sciences and pharmaceutical companies have analyzed genetic variation and function using a variety of technologies. In order to be successful, our products must meet the commercial requirements of the life sciences and pharmaceutical industries as tools for the large-scale analysis of genetic variation and function. Market acceptance will depend on many factors, including: ) our ability to demonstrate to potential customers the beneﬁts and cost effectiveness of our products and services relative to others available in the market; ) the extent and effectiveness of our efforts to market, sell and distribute our products; ) our ability to manufacture products in sufﬁcient quantities with acceptable quality and reliability and at an acceptable cost; and ) the willingness and ability of customers to adopt new technologies requiring capital investments. 38 Any inability to adequately protect our proprietary technologies could harm our competitive position. Our success will depend in part on our ability to obtain patents and maintain adequate protection of our intellectual property in the United States and other countries. If we do not protect our intellectual property adequately, competitors may be able to use our technologies and thereby erode our competitive advantage. The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered signiﬁcant problems in protecting their proprietary rights abroad. These problems can be caused by the absence of rules and methods for defending intellectual property rights. The patent positions of companies developing tools for the life sciences and pharmaceutical industries, including our patent position, generally are uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will apply for patents covering our technologies and products, as we deem appropriate. However, our patent applications may be challenged and may not result in issued patents. Our existing patents and any future patents we obtain may not be sufﬁciently broad to prevent others from practicing our technologies or from developing competing products. There also is risk that others may independently develop similar or alternative technologies or design around our patented technologies. Also, our patents may fail to provide us with any competitive advantage. We may need to initiate additional lawsuits to protect or enforce our patents, or litigate against third party claims, which would be expensive and, if we lose, may cause us to lose some of our intellectual property rights and reduce our ability to compete in the marketplace. We also rely upon trade secret protection for our conﬁdential and proprietary information. We have taken security measures to protect our proprietary information. These measures, however, may not provide adequate protection for our trade secrets or other proprietary information. We seek to protect our proprietary information by entering into conﬁdentiality agreements with employees, collaborators and consultants. Nevertheless, employees, collaborators or consultants may still disclose our proprietary information, and we may not be able to meaningfully protect our trade secrets. In addition, others may independently develop substantially equivalent proprietary information or techniques or otherwise gain access to our trade secrets. We have limited experience in manufacturing commercial products. We have limited experience manufacturing our products in the volumes that will be necessary for us to achieve signiﬁcant commercial sales. We have only recently begun manufacturing products on a commercial-scale and, in the past, we have experienced variations in manufacturing conditions that have temporarily reduced production yields. Due to the intricate nature of manufacturing products that contain DNA, we may encounter similar or previously unknown manufacturing difﬁculties in the future that could signiﬁcantly reduce production yields, impact our ability to launch or sell these products, or to produce them economically, may prevent us from achieving expected performance levels or cause us to set prices that hinder wide adoption by customers. 39 Our sales, marketing and technical support organization may limit our ability to sell our products. We currently have fewer resources available for sales and marketing and technical support services as compared to our primary competitors and have only recently established a small direct sales force and customer support team. In order to effectively commercialize our genotyping and gene expression systems and other products to follow, we will need to expand our sales, marketing and technical support staff both domestically and internationally. We may not be successful in establishing or maintaining either a direct sales force or distribution arrangements to market our products and services. In addition, we compete primarily with much larger companies, that have larger sales and distribution staffs and a signiﬁcant installed base of products in place, and the efforts from a limited sales and marketing force may not be sufﬁcient to build the market acceptance of our products required to support continued growth of our business. If we are unable to develop and maintain operation of our manufacturing capability, we may not be able to launch or support our products in a timely manner, or at all. We currently possess only one facility capable of manufacturing our products and services for both sale to our customers and internal use. If a natural disaster were to signiﬁcantly damage our facility or if other events were to cause our operations to fail, these events could prevent us from developing and manufacturing our products and services. If we are unable to ﬁnd third-party manufacturers to manufacture components of our products, we may not be able to launch or support our products in a timely manner, or at all. The nature of our products requires customized components that currently are available from a limited number of sources. For example, we currently obtain the ﬁber optic bundles and BeadChip slides included in our products from single vendors. If we are unable to secure a sufﬁcient supply of those or other product components, we will be unable to meet demand for our products. We may need to enter into contractual relationships with manufacturers for commercial-scale production of some of our products, or develop these capabilities internally, and we cannot assure you that we will be able to do this on a timely basis, for sufﬁcient quantities or on commercially reasonable terms. Accordingly, we may not be able to establish or maintain reliable, high-volume manufacturing at commercially reasonable costs. We may encounter difﬁculties in managing our growth. These difﬁculties could increase our losses. We expect to experience rapid and substantial growth in order to achieve our operating plans, which will place a strain on our human and capital resources. If we are unable to manage this growth effectively, our losses could increase. Our ability to manage our operations and growth effectively requires us to continue to expend funds to enhance our operational, ﬁnancial and management controls, reporting systems and procedures and to attract and retain sufﬁcient numbers of talented employees. If we are unable to scale up and implement improvements to our manufacturing process and control systems in an efﬁcient or timely manner, or if we encounter deﬁciencies in existing systems and controls, then we will not be able to make available the products required to successfully commercialize our technology. Failure to attract and retain sufﬁcient numbers of talented employees will further strain our human resources and could impede our growth. 40 We may need additional capital in the future. If additional capital is not available on acceptable terms, we may have to curtail or cease operations. Our future capital requirements will be substantial and will depend on many factors including our ability to successfully market our genetic analysis systems and services, the need for capital expendi- tures to support and expand our business, the progress and scope of our research and development projects, the ﬁling, prosecution and enforcement of patent claims, the outcome of our legal proceed- ings with Affymetrix and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. We anticipate that our existing capital resources will enable us to maintain currently planned operations for at least 24 months. However, we premise this expectation on our current operating plan, which may change as a result of many factors. Consequently, we may need additional funding within this timeframe. Our inability to raise capital would seriously harm our business and product development efforts. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, such as an acquisition, even if we believe we have sufﬁcient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity, the issuance of these securities could result in dilution to our stockholders. We currently have no credit facility or committed sources of capital available as of January 2, 2005. To the extent operating and capital resources are insufﬁcient to meet future requirements; we will have to raise additional funds to continue the development and commercialization of our technologies. These funds may not be available on favorable terms, or at all. If adequate funds are not available on attractive terms, we may be required to curtail operations signiﬁcantly or to obtain funds by entering into ﬁnancing, supply or collaboration agreements on unattractive terms. If we lose our key personnel or are unable to attract and retain additional personnel, we may be unable to achieve our goals. We are highly dependent on our management and scientiﬁc personnel, including Jay Flatley, our president and chief executive ofﬁcer, David Barker, our vice president and chief scientiﬁc ofﬁcer, and John Stuelpnagel, our senior vice president and chief operating ofﬁcer. The loss of their services could adversely impact our ability to achieve our business objectives. In addition, Timothy Kish, our chief ﬁnancial ofﬁcer, has informed us of his intention to resign in the second quarter of 2005. Mr. Kish continues in his role as chief ﬁnancial ofﬁcer, and we are currently conducting a search for his successor. We will need to hire additional qualiﬁed personnel with expertise in molecular biology, chemistry, biological information processing, sales, marketing and technical support. We compete for qualiﬁed management and scientiﬁc personnel with other life science companies, universities and research institutions, particularly those focusing on genomics. Competition for these individuals, particularly in the San Diego area, is intense, and the turnover rate can be high. Failure to attract and retain management and scientiﬁc personnel would prevent us from pursuing collaborations or developing our products or technologies. Our planned activities will require additional expertise in speciﬁc industries and areas applicable to the products developed through our technologies, including the life sciences and healthcare indus- tries. Thus, we will need to add new personnel, including management, and develop the expertise of existing management. The failure to do so could impair the growth of our business. 41 We may encounter difﬁculties in integrating future acquisitions and that could adversely affect our business. We have recently signed a deﬁnitive agreement to acquire CyVera Corporation and may in the future acquire technology, products or businesses related to our current or future business. Our acquisition of CyVera is expected to close in March 2005; however, the closing is subject to satisfaction of customary closing conditions, and we cannot assure you this transaction will close in this timeframe or at all. We have limited experience in acquisition activities and may have to devote substantial time and resources in order to complete acquisitions. Further, these potential acquisitions entail risks, uncertainties and potential disruptions to our business. For example, we may not be able to successfully integrate a company’s operations, technologies, products and services, information systems and personnel into our business. An acquisition may further strain our existing ﬁnancial and managerial controls, and divert management’s attention away from our other business concerns. In connection with the CyVera acquisition, we will assume certain liabilities and hire certain employees of CyVera, which is expected to result in an increase in research and development expenses. There may also be unanticipated costs and liabilities associated with an acquisition that could adversely affect our operating results. A signiﬁcant portion of our sales are to international customers. Approximately 52% of our revenues for the year ended January 2, 2005 were derived from customers outside the United States. We intend to continue to expand our international presence and export sales to international customers and we expect the total amount of non-U.S. sales to continue to grow. Export sales entail a variety of risks, including: ) currency exchange ﬂuctuations; ) unexpected changes in legislative or regulatory requirements of foreign countries into which we import our products; ) difﬁculties in obtaining export licenses or other trade barriers and restrictions resulting in delivery delays; and ) signiﬁcant taxes or other burdens of complying with a variety of foreign laws. In addition, sales to international customers typically result in longer payment cycles and greater difﬁculty in accounts receivable collection. We are also subject to general geopolitical risks, such as political, social and economic instability and changes in diplomatic and trade relations. One or more of these factors could have a material adverse effect on our business, ﬁnancial condition and operating results. Our success depends upon the increasing availability of genetic information and the continued emergence and growth of markets for analysis of genetic variation and function. We design our products primarily for applications in the life sciences and pharmaceutical industries. The usefulness of our technology depends in part upon the availability of genetic data and its usefulness in identifying or treating disease. We are initially focusing on markets for analysis of genetic variation and function, namely SNP genotyping and gene expression proﬁling. Both of these markets are new and emerging, and they may not develop as quickly as we anticipate, or reach their full potential. Other methods of analysis of genetic variation and function may emerge and displace the methods we are developing. Also, researchers may not seek or be able to convert raw genetic data into medically valuable information through the analysis of genetic variation and function. If useful genetic data is not available or if our target markets do not develop in a timely manner, demand for our products may grow at a slower rate than we expect, and we may not be able to achieve or sustain proﬁtability. 42 We expect that our results of operations will ﬂuctuate. This ﬂuctuation could cause our stock price to decline. Our revenues are subject to ﬂuctuations due to the timing of sales of high-value products and services projects, the impact of seasonal spending patterns, the timing and amount of government grant funding programs, the timing and size of research projects our customers perform, changes in overall spending levels in the life sciences industry and other unpredictable factors that may affect customer ordering patterns. Given the difﬁculty in predicting the timing and magnitude of sales for our products and services, we may experience quarter-to-quarter ﬂuctuations in revenue resulting in the potential for a sequential decline in quarterly revenue. A large portion of our expenses are relatively ﬁxed, including expenses for facilities, equipment and personnel. In addition, we expect operating expenses to continue to increase signiﬁcantly. Accordingly, if revenue does not grow as anticipated, we may not be able to reduce our operating losses. Approximately 30% of our revenues for the year 2004 resulted from transactions that were funded under the International HapMap Project. We currently expect that most of the activities under this grant involving the Company and its customers will be completed in early 2005. Although we expect that the loss of revenues resulting from the completion of the HapMap grant may be offset by the planned commercial launch of our whole genome genotyping and gene expression arrays, combined with the continued expansion of our existing product lines, any signiﬁcant delays in the commercial launch of these products, unfavorable sales trends in our existing product lines, or impacts from the other factors mentioned above, could adversely affect our revenue growth in 2005 or cause a sequential decline in quarterly revenues. Due to the possibility of ﬂuctuations in our revenue and expenses, we believe that quarterly comparisons of our operating results are not a good indication of our future performance. If our operating results ﬂuctuate or do not meet the expectations of stock market analysts and investors, our stock price probably would decline. Item 7A. Quantitative and Qualitative Disclosures About Market Risk. Interest Rate Sensitivity Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio. The fair market value of ﬁxed rate securities may be adversely impacted by ﬂuctuations in interest rates while income earned on ﬂoating rate securities may decline as a result of decreases in interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. We have historically maintained a relatively short average maturity for our investment portfolio, and a hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would not materially affect the fair value of our interest sensitive ﬁnancial instruments. Foreign Currency Exchange Risk Although most of our revenue is realized in U.S. dollars, some portions of our revenue are realized in foreign currencies. As a result, our ﬁnancial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. The functional currencies of our subsidiaries are their respective local currencies. Accordingly, the accounts of these operations are translated from the local currency to the U.S. dollar using the current exchange rate in effect at the balance sheet date for the balance sheet accounts, and using the average exchange rate during the period for revenue and expense accounts. The effects of translation are recorded in accumulated other comprehensive income as a separate component of stockholders equity. 43 Exchange gains and losses arising from transactions denominated in foreign currencies are recorded in operations. In July 2004, we began hedging signiﬁcant foreign currency ﬁrm sales commitments and accounts receivable with forward contracts. We only use derivative ﬁnancial instruments to reduce foreign currency exchange rate risks; we do not hold any derivative ﬁnancial instruments for trading or speculative purposes. Our forward exchange contracts have been desig- nated as cash ﬂow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in other comprehensive income. Realized gains and losses for the effective portion are recognized with the underlying hedge transaction. The notional settlement amount of the foreign currency forward contracts outstanding at January 2, 2005 was approximately $4.0 million. These contracts had a fair value of approximately $0.2 million, representing an unrealized loss, and were included in other current liabilities at January 2, 2005. As of January 2, 2005, all contracts were set to expire at various times through July 29, 2005 and are with reputable bank institutions. For the year ended January 2, 2005, there were no amounts recognized in earnings due to hedge ineffectiveness and we settled foreign exchange contracts of approximately $0.3 million. We have hedged all signiﬁcant ﬁrm commitments denominated in foreign currencies, and as a result, any increase or decrease in the exchange rates of these commitments would have no net effect to our balance sheet or our results of operations. Item 8. Financial Statements and Supplementary Data. The Report of Independent Registered Public Accounting Firm, Financial Statements and Notes to Financial Statements begin on page F-1 immediately following the signature page and are incorpo- rated herein by reference. Our ﬁscal year is 52 or 53 weeks ending on the Sunday closest to December 31, with quarters of 13 or 14 weeks ending on the Sunday closest to March 31, June 30 and September 30. The years ended January 2, 2005 and December 28, 2003 are 53 and 52 weeks, respectively. Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure. None. Item 9A. Controls and Procedures. We have established and maintain disclosure controls and procedures to ensure that we record, process, summarize, and report information we are required to disclose in our periodic reports ﬁled with the Securities and Exchange Commission in the manner and within the time periods speciﬁed in the SEC’s rules and forms. We also design our disclosure controls to ensure that the information is accumulated and communicated to our management, including the chief executive ofﬁcer and the chief ﬁnancial ofﬁcer, as appropriate to allow timely decisions regarding required disclosure. We also maintain internal controls and procedures to ensure that we comply with applicable laws and our established ﬁnancial policies. We design our internal controls to provide reasonable assurance that (1) our transactions are properly authorized; (2) our assets are safeguarded against unauthorized or improper use; and (3) our transactions are properly recorded and reported in conformity with accounting principles generally accepted in the United States. 44 We have evaluated the design and operation of our disclosure controls and procedures to determine whether they are effective in ensuring that the disclosure of required information is timely made in accordance with the Exchange Act and the rules and regulations of the Securities and Exchange Commission. This evaluation was made under the supervision and with the participation of management, including our chief executive ofﬁcer and chief ﬁnancial ofﬁcer as of January 2, 2005. Our management does not expect that our disclosure controls or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reﬂect the fact that there are resource constraints, and the beneﬁts of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The chief executive ofﬁcer and chief ﬁnancial ofﬁcer have concluded, based on their review, that our disclosure controls and procedures, as deﬁned by Exchange Act Rules 13a-15(e) and 15d-15(e), are effective to ensure that information required to be disclosed by us in reports that we ﬁle under the Exchange Act is recorded, processed, summarized and reported within the time periods speciﬁed in the Securities and Exchange Commission rules and forms. In addition, no change in our internal control over ﬁnancial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over ﬁnancial reporting has occurred during the fourth quarter of 2004. Management’s Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over ﬁnancial reporting, as such term is deﬁned in Exchange Act Rules 13a-15(f). Because of its inherent limitations, internal control over ﬁnancial reporting may not prevent or detect misstatements. There- fore, even those systems determined to be effective can provide only reasonable assurance with respect to ﬁnancial statement preparation and presentation. We conducted an evaluation of the effectiveness of our internal control over ﬁnancial reporting based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control — Integrated Framework, our management concluded that our internal control over ﬁnancial reporting was effective as of January 2, 2005. Our management’s assessment of the effectiveness of our internal control over ﬁnancial reporting as of January 2, 2005 has been audited by Ernst & Young LLP, Independent Registered Public Accounting Firm, as stated in their report which is included on page F-3 herein. Item 9B. Other Information. None. 45 Item 10. Directors and Executive Ofﬁcers of the Registrant. PART III (a) Identiﬁcation of Directors. Information concerning our directors is incorporated by reference from the section entitled ‘‘Proposal 1 — Election of Directors’’ contained in our deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. (b) Identiﬁcation of Executive Ofﬁcers. Information concerning our executive ofﬁcers is set forth under ‘‘Executive Ofﬁcers’’ in Part I of this Annual Report on Form 10-K and is incorporated herein by reference. (c) Compliance with Section 16(a) of the Exchange Act. Information concerning compliance with Section 16(a) of the Securities Exchange Act of 1934 is incorporated by reference from the section entitled ‘‘Compliance with Section 16(a) of the Securities Exchange Act’’ contained in our deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. (d) Information concerning the audit committee ﬁnancial expert as deﬁned by the SEC rules adopted pursuant to the Sarbanes-Oxley Act of 2002 is incorporated by reference from our deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. Code of Ethics We have adopted a code of ethics for our directors, ofﬁcers and employees, which is available on our website at www.illumina.com in the Corporate Governance section under ‘‘Investors’’. The information on our website is not incorporated by reference into this report. Item 11. Executive Compensation. Information concerning executive compensation is incorporated by reference from the sections entitled ‘‘Executive Compensation and Other Information’’ contained in our deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. Item 12. Security Ownership of Certain Beneﬁcial Owners and Management. Information concerning the security ownership of certain beneﬁcial owners and management is incorporated by reference from the section entitled ‘‘Ownership of Securities’’ contained in our deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. 46 Equity Compensation Plan Information The following table presents information about our common stock that may be issued upon the exercise of options, warrants and rights under all our existing equity compensation plans as of January 2, 2005. We currently have two equity compensation plans, the 2000 employee stock purchase plan and the 2000 stock plan; prior to our initial public offering we granted options under the 1998 stock incentive plan. All of these plans have been approved by our stockholders. Options outstanding include options granted under both the 1998 stock incentive plan and the 2000 stock plan. Plan Category Equity compensation plans approved by security holders Equity compensation plans not approved by security holders Total************************** (a) Number of Securities to be Issued Upon Exercise of Outstanding Options 6,206,020 — 6,206,020 (b) Weighted- Average Exercise Price of Outstanding Options $6.99 $ — $6.99 (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reﬂected in Column (a)) 5,964,649 — 5,964,649 Please refer to Note 6 in notes to consolidated ﬁnancial statements included in our annual report on Form 10-K for the year ended January 2, 2005 for a description of our equity compensation plans. Item 13. Certain Relationships and Related Transactions. Information concerning certain relationships and related transactions is incorporated by reference from the sections entitled ‘‘Proposal One: Election of Directors,’’ ‘‘Executive Compensation and Other Information’’ and ‘‘Certain Transactions’’ contained in our Deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. Item 14. Principal Accounting Fees and Services. Information concerning principal accounting fees and services is incorporated by reference from the sections entitled ‘‘Proposal Two: Ratiﬁcation of Independent Auditors’’ contained in our Deﬁnitive Proxy Statement with respect to our 2005 Annual Meeting of Stockholders to be ﬁled with the SEC no later than April 26, 2005. 47 Item 15. Exhibits, Financial Statement Schedules. PART IV (a) The following documents are ﬁled as a part of this report: (1) Consolidated Financial Statements: Index to Consolidated Financial Statements ************************************ Report of Ernst & Young LLP, Independent Registered Public Accounting Firm ***** Report of Ernst & Young LLP, Independent Registered Public Accounting Firm on Internal Control over Financial Reporting ******************************* Consolidated Balance Sheets as of January 2, 2005 and December 28, 2003 ****** Consolidated Statements of Operations for the years Ended January 2, 2005, December 28, 2003 and December 29, 2002 ********************************* Consolidated Statements of Stockholders’ Equity for the period from December 31, 2000 to January 2, 2005**************************************************** Consolidated Statements of Cash ﬂows for the years Ended January 2, 2005, December 28, 2003 and December 29, 2002 ********************************* Notes to Consolidated Financial Statements ************************************ (2) Financial Statement Schedules: Page F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 Valuation and Qualifying Account and Reserves for the three year period ended January 2, 2005 *********************************************************** F-28 (3) Exhibits: Exhibit Number 2.1(1) 3.1(2) 3.2(1) 3.3(5) 4.1(1) 4.2(1) 4.3(5) +10.1(1) +10.2(1) +10.3(2) 10.4(1) 10.5(1) 10.6(1) 10.7(1) Description of Document Form of Merger Agreement between Illumina, Inc., a California corporation, and Illumina, Inc., a Delaware corporation. Amended and Restated Certiﬁcate of Incorporation. Bylaws. Certiﬁcate of Designation for Series A Junior Participating Preferred Stock (included as an exhibit to exhibit 4.3). Specimen Common Stock Certiﬁcate. Amended and Restated Investors Rights Agreement, dated November 5, 1999, by and among the Registrant and certain stockholders of the Registrant. Rights Agreement, dated as of May 3, 2001, between the Company and Equiserve Trust Company, N.A. Form of Indemniﬁcation Agreement between the Registrant and each of its directors and ofﬁcers. 1998 Incentive Stock Plan. 2000 Employee Stock Purchase Plan (Filed as Exhibit 99.2). Sublease Agreement dated August 1998 between Registrant and Gensia Sicor Inc. for Illumina’s principal ofﬁces. Joint Development Agreement dated November 1999 between Registrant and PE Corporation (with certain conﬁdential portions omitted). Asset Purchase Agreement dated November 1998 between Registrant and nGenetics, Inc. (with certain conﬁdential portions omitted). Asset Purchase Agreement dated March 2000 between Registrant and Spyder Instruments, Inc. (with certain conﬁdential portions omitted). 48 Exhibit Number 10.8(1) 10.9(1) +10.10(3) 10.11(1) Description of Document License Agreement dated May 1998 between Tufts and Registrant (with certain conﬁdential portions omitted). Master Loan and Security Agreement, dated March 6, 2000, by and between Registrant and FINOVA Capital Corporation. 2000 Stock Plan (Filed as Exhibit 99.1). Eastgate Pointe Lease, dated July 6, 2000, between Diversiﬁed Eastgate Venture and Registrant. 10.12(1) Option Agreement and Joint Escrow Instructions, dated July 6, 2000, between Diversiﬁed 10.13(4) 10.14(6) 10.15(7) 10.16(7) 10.17(7) 10.18(8) 10.19(8) 10.20(8) Eastgate Venture and Registrant. First Amendment to Joint Development Agreement dated March 27, 2001 between Registrant and PE Corporation, now known as Applied Biosystems Group (with certain conﬁdential portions omitted). First Amendment to Option Agreement and Escrow Instructions dated May 25, 2001 between Diversiﬁed Eastgate Venture and Registrant. Second Amendment to Option Agreement and Escrow Instructions dated July 18, 2001 between Diversiﬁed Eastgate Venture and Registrant. Third Amendment to Option Agreement and Escrow Instructions dated September 27, 2001 between Diversiﬁed Eastgate Venture and Registrant. First Amendment to Eastgate Pointe Lease dated September 27, 2001 between Diversiﬁed Eastgate Venture and Registrant. Replacement Reserve Agreement, dated as of January 10, 2002, between the Company and BNY Western Trust Company as Trustee for Washington Capital Joint Master Trust Mortgage Income Fund. Loan Assumption and Modiﬁcation Agreement, dated as of January 10, 2002, between the Company, Diversiﬁed Eastgate Venture and BNY Western Trust Company as Trustee for Washington Capital Joint Master Trust Mortgage Income Fund. Tenant Improvement and Leasing Commission Reserve Agreement, dated as of January 10, 2002, between the Company and BNY Western Trust Company as Trustee for Washington Capital Joint Master Trust Mortgage Income Fund. 49 Exhibit Number +10.21(8) +10.22(8) 10.23(9) Description of Document 2000 Employee Stock Purchase Plan as amended on March 21, 2002. 2000 Stock Plan as amended on March 21, 2002. License Agreement dated January 2002 between Amersham Biosciences Corp. and Registrant (with certain conﬁdential portions omitted). 10.24(10) License Agreement dated June 2002 between Dade Behring Marburg GmbH and Registrant (with certain conﬁdential portions omitted). 10.25(11) Purchase and Sale Agreement and Escrow Instructions dated June 18, 2004 between Bernardo Property Advisors, Inc. and Registrant. 10.26(12) Single Tenant Lease dated August 18, 2004 between BioMed Realty Trust Inc. and Registrant. 10.27(12) Settlement and Cross License Agreement dated August 18, 2004 between Applera 10.28 10.29 14(10) 21 23.1 24.1 31.1 31.2 32.1 32.2 Corporation and Registrant (with certain conﬁdential portions omitted). Collaboration Agreement dated December 17, 2004 between Invitrogen Incorporated and Registrant (conﬁdential treatment has been requested with respect to certain portions of this exhibit). Forms of Stock Option Agreement under 2000 Stock Plan. Code of Ethics. Subsidiaries of the Company. Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm. Power of Attorney (included on the signature page). Certiﬁcation of Jay T. Flatley pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Certiﬁcation of Timothy M. Kish pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Certiﬁcation of Jay T. Flatley pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Certiﬁcation of Timothy M. Kish pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. + Management contract or corporate plan or arrangement (1) Incorporated by reference to the same numbered exhibit ﬁled with our Registration Statement on Form S-1 (333-33922) ﬁled April 3, 2000, as amended. (2) Incorporated by reference to the same numbered exhibit ﬁled with our Annual Report on Form 10-K for the year ended December 31, 2000. (3) Incorporated by reference to the corresponding exhibit ﬁled with our Registration Statement on Form S-8 ﬁled March 29, 2001. (4) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended March 31, 2001 ﬁled May 8, 2001. (5) Incorporated by reference to the same numbered exhibit ﬁled with our Registration Statement on Form 8-A (000-30361) ﬁled May 14, 2001. (6) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended June 30, 2001 ﬁled August 13, 2001. (7) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended September 30, 2001 ﬁled November 14, 2001. (8) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended March 31, 2002 ﬁled May 13, 2002. (9) Incorporated by reference to the same numbered exhibit ﬁled with Amendment No. 1 to our Registration Statement on Form S-3 (333-111496) ﬁled March 2, 2004. 50 (10) Incorporated by reference to the same numbered exhibit ﬁled with our Annual Report on Form 10-K for the year ended December 28, 2003. (11) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended June 27, 2004 ﬁled August 6, 2004. (12) Incorporated by reference to the same numbered exhibit ﬁled with our Form 10-Q for the quarterly period ended October 3, 2004 ﬁled November 12, 2004. Supplemental Information No Annual Report to stockholders or proxy materials has been sent to stockholders as of the date of this report. The Annual Report to stockholders and proxy material will be furnished to our stockholders subsequent to the ﬁling of this report and we will furnish such material to the SEC at that time. 51 SIGNATURES Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 8, 2005. ILLUMINA, INC. By: /s/ JAY T. FLATLEY Jay T. Flatley President and Chief Executive Ofﬁcer March 8, 2005 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints Jay T. Flatley and Timothy M. Kish, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to ﬁle the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and conﬁrming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. /s / JAY T. FLATLEY Jay T. Flatley /s/ TIMOTHY M. KISH Timothy M. Kish /s/ JOHN R. STUELPNAGEL John R. Stuelpnagel /s/ DANIEL M. BRADBURY Daniel M. Bradbury /s / KARIN EASTHAM Karin Eastham President and Chief Executive Ofﬁcer Director (Principal Executive Ofﬁcer) March 8, 2005 Vice President and Chief Financial Ofﬁcer (Principal Financial and Accounting Ofﬁcer) March 8, 2005 Senior Vice President and Chief Operating Ofﬁcer Director March 8, 2005 Director March 8, 2005 Director March 8, 2005 52 /s/ R. SCOTT GREER R. Scott Greer /s/ WILLIAM H. RASTETTER William H. Rastetter /s/ DAVID R. WALT David R. Walt Director March 8, 2005 Director March 8, 2005 Director March 8, 2005 53 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Ernst & Young LLP, Independent Registered Public Accounting Firm *************** F-2 Report of Ernst & Young LLP, Independent Registered Public Accounting Firm on Internal Control over Financial Reporting ****************************************************** F-3 Consolidated Balance Sheets as of January 2, 2005 and December 28, 2003***************** F-4 Consolidated Statements of Operations for the years ended January 2, 2005, December 28, 2003 and December 29, 2002********************************************************* F-5 Consolidated Statements of Stockholders’ Equity for the period from December 30, 2001 to January 2, 2005 ********************************************************************* F-6 Consolidated Statements of Cash Flows for the years ended January 2, 2005, December 28, 2003 and December 29, 2002********************************************************* F-7 Notes to Consolidated Financial Statements ********************************************** F-8 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors and Stockholders Illumina, Inc. We have audited the accompanying consolidated balance sheets of Illumina, Inc. as of January 2, 2005 and December 28, 2003, and the related consolidated statements of operations, stockholders’ equity, and cash ﬂows for the years ended January 2, 2005, December 28, 2003 and December 29, 2002. Our audits also include the ﬁnancial statement schedule listed in the Index at Item 15(a). These ﬁnancial statements and schedule are the responsibility of the Company’s management. Our responsi- bility is to express an opinion on these ﬁnancial statements and schedule based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the ﬁnancial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the ﬁnancial statements. An audit also includes assessing the accounting principles used and signiﬁcant estimates made by management, as well as evaluating the overall ﬁnancial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the ﬁnancial statements referred to above present fairly, in all material respects, the consolidated ﬁnancial position of Illumina, Inc. at January 2, 2005 and December 28, 2003, and the results of its operations and its cash ﬂows for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related ﬁnancial statement schedule, when considered in relation to the basic consoli- dated ﬁnancial statements taken as a whole, presents fairly in all material respects the information set forth therein. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Illumina, Inc.’s internal control over ﬁnancial reporting as of January 2, 2005, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 16, 2005 expressed an unqualiﬁed opinion thereon. San Diego, California February 16, 2004 /s/ ERNST & YOUNG LLP F-2 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL CONTROL OVER FINANCIAL REPORTING The Board of Directors and Stockholders Illumina, Inc. We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control over Financial Reporting, that Illumina, Inc. maintained effective internal control over ﬁnancial reporting as of January 2, 2005, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Illumina Inc.’s management is responsible for maintaining effective internal control over ﬁnancial reporting and for its assessment of the effectiveness of internal control over ﬁnancial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the company’s internal control over ﬁnancial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over ﬁnancial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over ﬁnancial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over ﬁnancial reporting is a process designed to provide reasonable assurance regarding the reliability of ﬁnancial reporting and the preparation of ﬁnancial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over ﬁnancial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reﬂect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of ﬁnancial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the ﬁnancial statements. Because of its inherent limitations, internal control over ﬁnancial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, management’s assessment that Illumina, Inc. maintained effective internal control over ﬁnancial reporting as of January 2, 2005, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, Illumina, Inc. maintained, in all material respects, effective internal control over ﬁnancial reporting as of January 2, 2005, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Illumina, Inc. as of January 2, 2005 and December 28, 2003, and the related consolidated statements of operations, stockholders’ equity, and cash ﬂows for the years ended January 2, 2005, December 28, 2003 and December 29, 2002 of Illumina, Inc. and our report dated February 16, 2005 expressed an unqualiﬁed opinion thereon. San Diego, California February 16, 2005 /s/ ERNST & YOUNG LLP F-3 ILLUMINA, INC. CONSOLIDATED BALANCE SHEETS December 28, January 2, 2003 2005 (In thousands, except share amounts) ASSETS Current assets: Cash and cash equivalents ************************************** $ 54,789 Investments, available for sale *********************************** — Restricted cash and investments ********************************* 12,205 Accounts receivable, net **************************************** 11,891 Inventory, net ************************************************** 3,807 Prepaid expenses and other current assets ************************ 999 Total current assets ***************************************** Property and equipment, net **************************************** Long-term restricted investments ************************************ Intangible and other assets, net ************************************* 83,691 8,574 — 2,642 Total assets ************************************************ $ 94,907 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable ********************************************** $ Accrued liabilities ********************************************** Litigation judgment********************************************* Current portion of long-term debt ******************************* Current portion of equipment ﬁnancing*************************** Total current liabilities ************************************** Long-term debt, less current portion ********************************* Advance payment from former collaborator *************************** Litigation judgment************************************************* Deferred gain on sale of land and building *************************** Other long term liabilities ******************************************* Commitments and contingencies Stockholders’ equity: 2,684 10,407 5,957 — — 19,048 — — — 3,218 379 $ 12,465 20,317 100 4,549 2,022 965 40,418 45,777 12,191 848 $ 99,234 $ 2,030 5,540 — 366 253 8,189 24,999 10,000 8,658 — — Common stock, $.01 par value, 120,000,000 shares authorized, 38,120,685 shares issued and outstanding at January 2, 2005, 32,886,693 shares issued and outstanding at December 28, 2003 Additional paid-in capital *************************************** Deferred compensation ***************************************** Accumulated other comprehensive income *********************** Accumulated deﬁcit ******************************************** Total stockholders’ equity *********************************** 72,262 Total liabilities and stockholders’ equity*********************** $ 94,907 381 195,653 (156) 96 (123,712) 329 165,314 (1,103) 335 (117,487) 47,388 $ 99,234 See accompanying notes. F-4 ILLUMINA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended January 2, 2005 (In thousands except per share amounts) Year Ended December 28, 2003 Year Ended December 29, 2002 Revenue ********************************************* Product revenue ********************************** Service revenue ********************************** Research revenue ********************************* Total revenue********************************* Costs and expenses: Cost of product revenue*************************** Cost of service revenue *************************** Research and development ************************ Selling, general and administrative ***************** Amortization of deferred compensation and other stock-based compensation charges *************** Litigation judgment (settlement) ******************** Total costs and expenses ********************** Loss from operations ********************************** Interest income *************************************** Interest and other expense **************************** Net loss ********************************************* Net loss per share, basic and diluted ******************* $40,497 8,075 2,011 50,583 $ 18,378 6,496 3,161 28,035 $ 4,103 3,305 2,632 10,040 11,572 1,687 21,114 25,080 844 (4,201) 56,096 (5,513) 941 (1,653) 7,437 2,600 22,511 18,899 2,454 756 54,657 (26,622) 1,821 (2,262) 1,815 1,721 26,848 9,099 4,360 8,052 51,895 (41,855) 3,805 (2,281) $ (6,225) $(27,063) $(40,331) $ (0.17) $ (0.85) $ (1.31) Shares used in calculating net loss per share, basic and diluted ******************************************** 35,845 31,925 30,890 The composition of stock-based compensation is as follows: Research and development ************************** Selling, general and administrative ******************* $ $ 348 496 844 $ 1,289 1,165 $ 2,454 $ 2,399 1,961 $ 4,360 See accompanying notes. F-5 l a t o T l d e t a u m u c c r e h t O I Y A T U Q E l ’ s r e d o h k c o t S l d e t a u m u c c A y t i u q E t i c ﬁ e D e v i s n e h e r p m o C ) s s o L ( e m o c n I d e r r e f e D n o i t a s n e p m o c ) s d n a s u o h t n I ( 6 9 6 0 6 3 , 4 — 1 9 7 , 6 0 1 8 2 2 ) 1 3 3 , 0 4 ( ) 3 0 1 , 0 4 ( 3 0 9 4 4 7 , 1 7 ) 8 ( — 4 5 4 , 2 0 6 ) 2 0 7 ( ) 3 6 0 , 7 2 ( ) 3 1 ( 4 4 8 — ) 5 0 7 , 7 2 ( 8 8 3 , 7 4 7 0 5 , 0 3 ) 5 0 3 ( ) 6 4 ( 2 1 1 ) 5 2 2 , 6 ( ) 4 6 4 , 6 ( ) 3 9 0 , 0 5 ( — — — — ) 1 3 3 , 0 4 ( ) 4 2 4 , 0 9 ( — — — — — — ) 3 6 0 , 7 2 ( — — — — — — — ) 5 2 2 , 6 ( ) 7 8 4 , 7 1 1 ( 9 4 7 — — — — 8 2 2 7 7 9 — — — — ) 2 0 7 ( 0 6 — — — — — 5 3 3 ) 5 0 3 ( ) 6 4 ( — 2 1 1 . C N I , I A N M U L L I S R E D L O H K C O T S F O S T N E M E T A T S D E T A D I L O S N O C ) 3 8 0 , 8 ( l a n o i t i d d A n I - i d a P k c o t S n o m m o C l a t i p a C t n u o m A s e r a h S 6 9 8 , 3 6 1 2 2 3 4 3 2 , 2 3 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 1 0 0 2 , 0 3 r e b m e c e D t a e c n a a B l — 0 6 3 , 4 — 3 9 6 6 0 1 — — ) 6 0 1 ( — — 3 — — — — ) 7 1 6 , 3 ( 3 8 4 , 4 6 1 5 2 3 — — ) 8 ( 9 9 8 2 4 4 , 2 2 1 2 7 — — — — — 4 4 8 3 0 1 — — — — ) 3 0 1 , 1 ( ) 2 7 ( — — — 4 5 4 , 0 3 4 1 3 , 5 6 1 ) 2 1 ( — ) 3 0 1 ( — — — — 4 — — — — — — 3 5 ) 1 ( — 9 2 3 — — — — — — 6 6 2 — — — 8 0 4 0 0 5 , 2 3 ) 1 2 ( — — — — — 8 7 2 , 5 7 8 8 , 2 3 ) 4 4 ( — — — — — — * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * d e s a h c r u p e r f o t e n , h s a c r o f k c o t s n o m m o c f o s e r a h s e c n a u s s I * * * * * * * * * * * * * * * * * * n o i t a s n e p m o c d e r r e f e d f o n o i t a z i t r o m A d e t s e v n u o t d e t a e r l n o i t a s n e p m o c d e r r e f e d f o l a s r e v e R * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * d e t a n m r e t i f o k c o t s d e t c i r t s e r d n a s n o i t p o k c o t s s e e y o p m e l * * * * * * * * * * * * s e i t i r u c e s l e a s - r o f - e b a l l i a v a n o i n a g d e z i l a e r n U : s s o l e v i s n e h e r p m o C * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l t e N * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l e v i s n e h e r p m o C * * * * * * * * * * * * * * * * * * * * * * h s a c r o f k c o t s n o m m o c f o e c n a u s s I * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * k c o t s n o m m o c d e t c i r t s e r f o e s a h c r u p e R n o i t a s n e p m o c d e r r e f e d f o n o i t a z i t r o m A * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 2 0 0 2 , 9 2 r e b m e c e D t a e c n a a B l d e t s e v n u o t d e t a e r l n o i t a s n e p m o c d e r r e f e d f o l a s r e v e R * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * d e t a n m r e t i f o k c o t s d e t c i r t s e r d n a s n o i t p o k c o t s s e e y o p m e l * * * * * * * * * * * * s e i t i r u c e s l e a s r o f - e b a l l i a v a n o i n a g d e z i l a e r n U * * * * * * * * * * * * * * * * * * t n e m t s u d a j n o i t a l s n a r t y c n e r r u c i n g e r o F * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l t e N : s s o l e v i s n e h e r p m o C * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l e v i s n e h e r p m o C * * * * * * * * * * * * * * * * * * * * * * h s a c r o f k c o t s n o m m o c f o e c n a u s s I * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * k c o t s n o m m o c d e t c i r t s e r f o e s a h c r u p e R n o i t a s n e p m o c d e r r e f e d f o n o i t a z i t r o m A * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 3 0 0 2 , 8 2 r e b m e c e D t a e c n a a B l d e t s e v n u o t d e t a e r l n o i t a s n e p m o c d e r r e f e d f o l a s r e v e R F-6 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * d e t a n m r e t i f o k c o t s d e t c i r t s e r d n a s n o i t p o k c o t s s e e y o p m e l * * * * * * * * * * * * * s e i t i r u c e s l e a s - r o f - e b a l l i a v a n o s s o l d e z i l a e r n U : s s o l e v i s n e h e r p m o C * * * * * * * * * * * * * * * * * * * * s t c a r t n o c i g n g d e h n o s s o l d e z i l a e r n U * * * * * * * * * * * * * * * * * * t n e m t s u d a j n o i t a l s n a r t y c n e r r u c i n g e r o F * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l t e N * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * s s o l e v i s n e h e r p m o C 2 6 2 , 2 7 $ ) 2 1 7 , 3 2 1 $ ( 6 9 $ ) 6 5 1 ( $ 3 5 6 , 5 9 1 $ 1 8 3 $ 1 2 1 , 8 3 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * 5 0 0 2 , 2 y r a u n a J t a e c n a a B l ILLUMINA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS Cash ﬂows from operating activities Net loss ********************************************** Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization************************* Loss on disposal of property and equipment************ Amortization of premium on investments *************** Amortization of deferred compensation and other stock- based compensation charges *********************** Amortization of gain on sale of land and building ******* Changes in operating assets and liabilities: Accounts receivable ******************************** Inventory****************************************** Prepaid expenses and other current assets *********** Other assets*************************************** Accounts payable ********************************** Accrued liabilities ********************************** Accrued litigation judgment************************* Other long term liabilities*************************** Advance payment from former collaborator*********** Net cash used in operating activities *************** Cash ﬂows from investing activities Purchases of available-for-sale securities ******************** Sales and maturities of available-for-sale securities ********** Proceeds from sale of land and building, net of fees********* Purchase of property and equipment*********************** Acquisition of intangible assets **************************** Net cash provided by (used in) investing activities *********** Cash ﬂows from ﬁnancing activities Proceeds from long-term debt **************************** Payments on long-term debt ****************************** Payments on equipment ﬁnancing ************************* Proceeds from issuance of common stock ****************** Repurchase of common stock ***************************** Net cash provided by ﬁnancing activities ******************* Effect of foreign currency translation on cash and cash equivalents ******************************************** Net increase (decrease) in cash and cash equivalents ******** Cash and cash equivalents at beginning of the year ********* Cash and cash equivalents at end of the year *************** Supplemental disclosures of cash ﬂow information: Cash paid during the year for interest ********************** Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Year Ended December 29, 2002 $ (6,225) $(27,063) $(40,331) 3,956 — 354 844 (156) (7,202) (1,785) (29) (2,041) 697 1,958 567 (512) (10,000) (19,574) (6,603) 26,348 40,667 (3,355) (35) 57,022 — (25,387) (232) 30,507 (13) 4,875 1 42,324 12,465 4,545 175 432 2,454 — (1,296) 277 8 (151) 260 1,742 606 (245) — 4,531 — 609 4,360 — (2,878) (1,328) 155 211 (205) 1,262 8,052 (31) — (18,256) (25,593) (1,940) 32,456 — (2,032) (16) 28,468 — (342) (337) 904 (9) 216 — 10,428 2,037 (116,568) 141,551 — (26,830) (794) (2,641) 26,000 (293) (297) 696 — 26,106 — (2,128) 4,165 $ 54,789 $ 12,465 $ 2,037 $ 1,368 $ 2,222 $ 2,263 See accompanying notes. F-7 ILLUMINA, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. Organization and Summary of Signiﬁcant Accounting Policies Organization and Business Illumina, Inc. (the ‘‘Company’’) was incorporated on April 28, 1998. The Company develops and markets next-generation tools for the large-scale analysis of genetic variation and function. Using the Company’s technologies, it has developed a comprehensive line of products that are designed to provide the throughput, cost effectiveness and ﬂexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. This information is expected to correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more speciﬁcally, and permitting better choices of drugs for individual patients. Basis of Presentation The consolidated ﬁnancial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Fiscal Year The Company’s ﬁscal year is 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, and September 30. The years ended January 2, 2005 and December 28, 2003 are 53 and 52 weeks, respectively. Use of Estimates The preparation of ﬁnancial statements requires that management make estimates and assump- tions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents are comprised of highly liquid investments with a remaining maturity of less than three months from the date of purchase. Investments The Company applies Statement of Financial Accounting Standards (‘‘SFAS’’) No. 115, Accounting for Certain Investments in Debt and Equity Securities, to its investments. Under SFAS No. 115, the Company classiﬁes its investments as ‘‘Available-for-Sale’’ and records such assets at estimated fair value in the balance sheet, with unrealized gains and losses, if any, reported in stockholders’ equity. The Company invests its excess cash balances in marketable debt securities, primarily government securities and corporate bonds and notes, with strong credit ratings or short maturity mutual funds providing similar ﬁnancial returns. The Company limits the amount of investment exposure as to institutions, maturity and investment type. The cost of securities sold is determined based on the speciﬁc identiﬁcation method. Gross realized gains totaled $453,750, $342,693 and $810,201 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. Gross realized losses totaled $891, $141 and $27,467 for the years ended January 2, 2005, December 28, 2003, and December 29, 2002, respectively. F-8 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Restricted Cash and Investments At January 2, 2005, restricted cash and investments consist of corporate debt securities that are used as collateral against a letter of credit and a $100,000 bond deposit with the San Diego Superior Court related to the Applied Biosystems litigation (see Note 7). At December 28, 2003, the restricted investments used as collateral against the letter of credit were classiﬁed as long term. Fair Value of Financial Instruments The carrying amounts of certain of the Company’s ﬁnancial instruments including cash and cash equivalents, accounts and notes receivable, accounts payable and accrued liabilities approximate fair value. The Company enters into foreign currency exchange forward contracts to minimize its exposure to foreign currency exchange ﬂuctuations and accounts for these derivatives in accordance with SFAS 133, Accounting for Derivative Instruments and Hedging Activities as described more fully in Note 3. Accounts and Notes Receivable Trade accounts receivable are recorded at net invoice value and notes receivable are recorded at contractual value plus earned interest. Interest income on notes receivable is recognized according to the terms of each related agreement. The Company considers receivables past due based on the contractual payment terms. The Company reviews its exposure to amounts receivable and reserves speciﬁc amounts if collectibility is no longer reasonably assured. The Company also reserves a percentage of the net trade receivable balance based on collection history. The Company re-evaluates such reserves on a regular basis and adjusts its reserves as needed. Concentrations of Risk Cash equivalents, investments and accounts receivable are ﬁnancial instruments that potentially subject the Company to concentrations of credit risk. Most of the Company’s cash and cash equivalents as of January 2, 2005 are deposited with ﬁnancial institutions in the United States and Company policy restricts the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued by the U.S. Government. The Company has historically not experienced signiﬁcant credit losses from accounts receivable. The Company performs a regular review of customer activity and associated credit risks and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectibility of accounts receivable. The Company’s products require customized components that currently are available from a limited number of sources. The Company obtains certain key components included in its products from single vendors. No assurance can be given that these or other product components will be available in sufﬁcient quantities at acceptable costs in the future. Approximately 52% of the Company’s revenues for the year ended January 2, 2005 were derived from customers outside the United States. International sales entail a variety of risks, including currency exchange ﬂuctuations, longer payment cycles and greater difﬁculty in accounts receivable collection. The Company is also subject to general geopolitical risks, such as political, social and economic instability and changes in diplomatic and trade relations. The risks of international sales are mitigated in part by the extent to which sales are geographically distributed and the Company’s foreign currency hedging program. F-9 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Inventories Inventories are stated at the lower of standard cost (which approximates actual cost) or market. Inventory includes raw materials and ﬁnished goods that may be used in the research and develop- ment process and such items are expensed as consumed. Provisions for slow moving, excess and obsolete inventories are provided based on product life cycle and development plans, product expiration and quality issues, historical experience and inventory levels. Property and Equipment Property and equipment are stated at cost, subject to review of impairment, and depreciated over the estimated useful lives of the assets (generally three to seven years for equipment) using the straight-line method. Amortization of leasehold improvements is computed over the shorter of the lease term or the estimated useful life of the related assets. Intangible Assets Intangible assets consist of license agreements and acquired technology. In accordance with Accounting Principles Board (‘‘APB’’) Opinion No. 17, Accounting for Intangible Assets, intangible assets are recorded at cost. The rights related to one of the license agreements are amortized over its estimated useful life (ﬁve years) and will be fully amortized in ﬁscal year 2008. The rights related to other license agreements are amortized based on sales of related product and are expected to be fully amortized by the end of ﬁscal 2005. The cost of these license agreements was $844,450 and the Company has amortized $493,333 through January 2, 2005. Amortization expense related to license agreements for the years ending January 2, 2005, December 28, 2003 and December 29, 2002 was $300,000, $185,000 and $8,333, respectively. Long-Lived Assets In accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, if indicators of impairment exist, the Company annually assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash ﬂows. If impairment is indicated, the Company measures the future discounted cash ﬂows associated with the use of the asset and adjusts the value of the asset accordingly. While the Company’s current and historical operating and cash ﬂow losses are indicators of impairment, the Company believes the future cash ﬂows to be received from the long-lived assets recorded at January 2, 2005 will exceed the assets’ carrying value, and accordingly the Company has not recognized any impairment losses through January 2, 2005. Reserve for Product Warranties The Company generally provides a one year warranty on genotyping and gene expression systems. At the time revenue is recognized, the Company establishes an accrual for estimated warranty expenses associated with system sales. This expense is recorded as a component of cost of revenue. F-10 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Revenue Recognition The Company records revenue in accordance with the guidelines established by SEC Staff Accounting Bulletin No. 104 (‘‘SAB 104’’). Under SAB 104, revenue cannot be recorded until all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller’s price to the buyer is ﬁxed or determinable; and collectibility is reasonably assured. Product revenue consists of sales of oligonucleotides, arrays, assay reagents, genotyping systems and gene expression systems. Service revenue consists of revenue received for performing SNP genotyping services and for extended warranty sales. Revenue for product sales is recognized generally upon shipment and transfer of title to the customer, provided no signiﬁcant obligations remain and collection of the receivables is reasonably assured. BeadLab revenue is recognized when earned, which is generally upon shipment, installation, training and fulﬁllment of contractually deﬁned acceptance criteria. Reserves are provided for antici- pated product warranty expenses at the time the associated revenue is recognized. Revenue for extended warranty sales is recognized ratably over the term of the extended warranty. Revenue for genotyping services is recognized generally at the time the genotyping analysis data is delivered to the customer. The Company has been awarded $9.1 million from the National Institutes of Health to perform genotyping services in connection with the ﬁrst phase of the International HapMap Project. A portion of the revenue from this project is earned at the time the related costs are incurred while the remainder of the revenue is earned upon the delivery of genotyping data. Research revenue consists of amounts earned under research agreements with government grants, which is recognized in the period during which the related costs are incurred. Some contracts entered into by the Company qualify as multiple element arrangements as deﬁned by Emerging Issues Task Force Issue No. 00-21 (‘‘EITF 00-21’’), ‘‘Revenue Arrangements with Multiple Deliverables.’’ The Company recognizes revenue for delivered elements only when the delivered element has stand-alone value, the fair values of undelivered elements are known, and there are no uncertainties regarding customer acceptance. All revenues are recognized net of applicable allowances for returns or discounts. Shipping and Handling Expenses Shipping and handling expenses are included in cost of product revenue and totaled $180,208, $143,423 and $45,809 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. F-11 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Research and Development Expenditures relating to research and development are expensed in the period incurred. Software Development Costs The Company applies Statement of Financial Accounting Standards No. 86, Accounting for the Costs of Computer Software to be Sold, Leased or Otherwise Marketed, to capitalize costs related to marketed software. To date, the Company has only marketed software that is an incidental component to its SNP genotyping and gene expression systems. Accordingly, the Company capitalizes software costs that are incurred after the later of 1) the establishment of technological feasibility of the software or 2) the completion of all research and development activities for the other components of the product. Through January 2, 2005, the period between achieving either of these milestones and the general release date of the products has been very brief and software development costs thereafter were not signiﬁcant. Accordingly, the Company has not capitalized any qualifying software develop- ment costs in the accompanying consolidated ﬁnancial statements. The costs of developing routine enhancements are expensed as research and development costs as incurred because of the short time between the determination of technological feasibility and the date of general release of the related products. The Company applies Statement of Position (‘‘SOP’’) No. 98-1, Accounting for the Costs of Computer Software Developed or Obtained for Internal Use. For the years ended January 2, 2005 and December 28, 2003, the Company capitalized $26,650 and $93,693, respectively, in costs incurred to acquire and develop software associated with the implementation of its Enterprise Resource Planning and Laboratory Information Management systems. These costs are amortized over the estimated useful life of the software of seven years, beginning when the software is ready for its intended use. Advertising Costs The Company expenses advertising costs as incurred. Advertising costs were $792,508, $439,710 and $267,338 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. Income Taxes A deferred income tax asset or liability is computed for the expected future impact of differences between the ﬁnancial reporting and tax bases of assets and liabilities, as well as the expected future tax beneﬁt to be derived from tax loss and credit carryforwards. Deferred income tax expense is generally the net change during the year in the deferred income tax asset or liability. Valuation allowances are established when realizability of deferred tax assets is uncertain. The effect of tax rate changes is reﬂected in tax expense during the period in which such changes are enacted. Foreign Currency Translation The functional currencies of the Company’s wholly owned subsidiaries are their respective local currencies. Accordingly, all balance sheet accounts of these operations are translated to U.S. dollars using the exchange rates in effect at the balance sheet date, and revenues and expenses are translated using the average exchange rates in effect during the period. The gains and losses from foreign currency translation of these subsidiaries’ ﬁnancial statements are recorded directly as a separate component of stockholders’ equity under the caption ‘‘Accumulated other comprehensive income.’’ F-12 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Stock-Based Compensation At January 2, 2005, the Company has three stock-based employee and non-employee director compensation plans, which are described more fully in Note 6. As permitted by SFAS No. 123, Accounting for Stock-Based Compensation,the Company accounts for common stock options granted, and restricted stock sold, to employees, founders and directors using the intrinsic value method and, thus, recognizes no compensation expense for options granted, or restricted stock sold, with exercise prices equal to or greater than the fair value of the Company’s common stock on the date of the grant. The Company has recorded deferred stock compensation related to certain stock options, and restricted stock, which were granted prior to the Company’s initial public offering with exercise prices below estimated fair value (see Note 6), which is being amortized on an accelerated amortization methodology in accordance with Financial Accounting Standards Board Interpretation Number (‘‘FIN’’) 28. Pro forma information regarding net loss is required by SFAS No. 123 and has been determined as if the Company had accounted for its employee stock options and employee stock purchases under the fair value method of that statement. The fair value for these options was estimated at the dates of grant using the fair value option pricing model (Black Scholes) with the following weighted-average assumptions for 2004, 2003 and 2002: Year Ended January 2, 2005 Year Ended December 28, 2003 Year Ended December 29, 2002 Weighted average risk-free interest rate ********* Expected dividend yield *********************** Weighted average volatility ******************** Estimated life (in years) ************************ Weighted average fair value of options granted** 3.25% 0% 97% 5 $5.25 3.03% 0% 103% 5 $3.31 3.73% 0% 104% 5 $4.39 For purposes of pro forma disclosures, the estimated fair value of the options is amortized to expense over the vesting period. The Company’s pro forma information is as follows (in thousands except per share amounts): Net loss as reported ************************** Add: Stock-based compensation expense recorded*********************************** Less: Assumed stock compensation expense***** Pro forma net loss **************************** Basic and Diluted net loss per share: As reported ********************************** Pro forma ************************************ Year Ended January 2, 2005 Year Ended December 28, 2003 Year Ended December 29, 2002 $ (6,225) $(27,063) $(40,331) 844 (9,217) 2,454 (8,576) 4,360 (8,479) $(14,598) $(33,185) $(44,450) $ $ (0.17) (0.41) $ $ (0.85) (1.04) $ $ (1.31) (1.44) The pro forma effect on net loss presented is not likely to be representative of the pro forma effects on reported net income or loss in future years because these amounts reﬂect less than ﬁve years of vesting. F-13 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. In December 2004, the Financial Accounting Standards Board (FASB) issued FASB Statement No. 123 (revised 2004), Share Based Payment (SFAS 123R), which is a revision of FASB Statement No. 123, Accounting for Stock-Based Compensation (SFAS 123). This statement supercedes APB Opinion 25, Accounting for Stock Issued to Employees (APB 25), and amends FASB Statement No. 95, Statement of Cash Flows. Generally, the approach in SFAS 123R is similar to the approach described in SFAS 123; however, SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Pro forma disclosure is no longer an alternative. SFAS 123R permits companies to adopt its requirements using either a ‘‘modiﬁed prospective’’ method or a ‘‘modiﬁed retrospective’’ method. Under the ‘‘modiﬁed prospective’’ method, compensa- tion cost is recognized in the ﬁnancial statements beginning with the effective date, based on the requirements of SFAS 123R for all share-based payments granted after that date, and based on the requirements for SFAS 123 for all unvested awards granted prior to the effective date of SFAS 123R. Under the ‘‘modiﬁed retrospective’’ method, the requirements are the same as under the ‘‘modiﬁed prospective’’ method, but also permits companies to restate ﬁnancial statements of previous periods based on proforma disclosures made in accordance with SFAS 123. The Company currently utilizes the Black-Scholes model to measure the fair value of stock options granted to employees under the pro forma disclosure requirements if FAS 123. While SFAS 123R permits companies to continue to use such model, it also permits the use of a ‘‘lattice’’ model. The Company has not yet determined which method or model it will use to measure the fair value of employee stock options under the adoption for SFAS 123R. The new standard is effective for periods beginning after June 15, 2005, and the Company expects to adopt SFAS 123R on July 4, 2005. The Company currently accounts for share-based payments to employees using APB 25’s intrinsic value method and, as such, recognizes no compensation cost for employee stock options granted with exercise prices equal to or greater than the fair value of the Company’s common stock on the date of the grant. Accordingly, the adoption of SFAS 123R’s fair value method is expected to result in signiﬁcant non-cash charges which will increase the Company’s reported operating expenses, however, it will have no impact on its cash ﬂows. The impact of adoption of SFAS 123R cannot be predicted at this time because it will depend on the level of share-based payments granted in the future and the model the Company chooses to use. However, had the Company adopted SFAS 123R in prior periods, the impact of that standard would have approximated the impact of SFAS 123 as described in the disclosure of pro forma net income and earnings above. Deferred compensation for options granted, and restricted stock sold, to consultants has been determined in accordance with SFAS No. 123 and Emerging Issues Task Force 96-18 as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Deferred charges for options granted, and restricted stock sold, to consultants are periodically remeasured as the underlying options vest. Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive loss. Other comprehensive loss includes unrealized gains and losses on the Company’s available-for-sale securities, changes in the fair value of derivatives designated as effective as cash ﬂow hedges, and foreign currency translation adjustments. The Company has disclosed comprehensive loss as a component of stockholders’ equity. F-14 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. The components of accumulated other comprehensive loss are as follows (in thousands): Year Ended January 2, 2005 Year Ended December 28, 2003 Foreign currency translation adjustments ********************** Unrealized loss on available-for-sale securities ***************** Unrealized loss on cash ﬂow hedges ************************* Accumulated other comprehensive loss *********************** $171 (29) (46) $ 96 $ 60 275 — $335 Net Loss per Share Basic and diluted net loss per common share are presented in conformity with SFAS No. 128, Earnings per Share, for all periods presented. In accordance with SFAS No. 128, basic and net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, less shares subject to repurchase. Diluted net loss per share is typically computed using the weighted average number of common and dilutive common equivalent shares from stock options using the treasury stock method. However, for all periods presented, diluted net loss per share is the same as basic net loss per share because the Company reported a net loss and therefore the inclusion of weighted average shares of common stock issuable upon the exercise of stock options would be antidilutive. Weighted-average shares outstanding ********** Less: Weighted-average shares of common stock subject to repurchase *********************** Weighted-average shares used in computing net loss per share, basic and diluted ************* Year Ended January 2, 2005 Year Ended December 28, 2003 (In thousands) Year Ended December 29, 2002 36,165 32,733 32,390 (320) (808) (1,500) 35,845 31,925 30,890 The total number of shares excluded from the calculation of diluted net loss per share, prior to application of the treasury stock method for options and warrants, was 6,360,023, 5,809,649 and 5,556,455 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. 2. Balance Sheet Account Details Investments, including restricted investments, consist of the following (in thousands): Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Market Value January 2, 2005 Restricted corporate debt securities ****************** Total ******************** $12,134 $12,134 $— $— $(29) $(29) $12,105 $12,105 F-15 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. December 28, 2003 Amortized Cost Gross Unrealized Gain Gross Unrealized Loss Market Value US Treasury securities ********* Corporate debt securities ***** Restricted corporate debt securities ****************** Total ******************** $ 6,340 13,480 19,820 12,413 $32,233 $253 244 497 — $497 $ — — — (222) $(222) $ 6,593 13,724 20,317 12,191 $32,508 As of January 2, 2005, all investments mature within one year. Accounts receivable consist of the following (in thousands): Accounts receivable from product and service sales ************* Notes receivable from product sales*************************** Accounts receivable from government grants******************* Other receivables ******************************************* Allowance for doubtful accounts ****************************** Total *************************************************** Inventory consists of the following (in thousands): January 2, 2005 December 28, 2003 $11,182 464 108 283 12,037 (146) $4,388 — 260 79 4,727 (178) $11,891 $4,549 January 2, 2005 December 28, 2003 Raw materials *********************************************** Work in process ********************************************* Finished goods ********************************************* Total *************************************************** $1,487 1,714 606 $3,807 $ 829 931 262 $2,022 Property and equipment consist of the following (in thousands): January 2, 2005 December 28, 2003 Land ******************************************************* $ Buildings *************************************************** Leasehold improvements************************************* Laboratory and manufacturing equipment********************** Computer equipment and software *************************** Furniture and ﬁxtures **************************************** — — 347 11,067 6,116 2,095 Accumulated depreciation and amortization ******************** 19,625 (11,051) Total *************************************************** $ 8,574 $ 10,361 29,479 174 9,221 5,130 1,966 56,331 (10,554) $ 45,777 F-16 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Depreciation expense was $3.7 million, $4.4 million and $4.5 million for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. Accrued liabilities consist of the following (in thousands): January 2, 2005 December 28, 2003 Compensation ********************************************** Professional fees ******************************************** Taxes ****************************************************** Reserve for product warranties******************************** Customer deposits ****************************************** Short-term deferred revenue ********************************* Short-term deferred gain on sale of building ******************* Other ****************************************************** Total *************************************************** $ 3,798 1,488 928 577 1,671 915 375 655 $10,407 $2,608 1,437 523 230 253 — — 489 $5,540 3. Derivative Financial Instruments SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, requires that all derivatives be recognized on the balance sheet at their fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether a derivative is designated as part of a hedge transaction and, if it is, the type of hedge transaction. We assess, both at its inception and on an on-going basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash ﬂows of hedged items. We also assess hedge ineffectiveness on a quarterly basis and record the gain or loss related to the ineffective portion to current earnings to the extent signiﬁcant. The Company has a foreign exchange hedging program principally designed to mitigate the potential impact due to changes in foreign currency exchange rates. The Company does not hold any derivative ﬁnancial instruments for trading or speculative purposes. The Company primarily uses forward exchange contracts to hedge foreign currency exposures and they generally have terms of one year or less. These contracts have been designated as cash ﬂow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in other comprehensive income. Realized gains and losses for the effective portion are recognized with the underlying hedge transaction. The notional settlement amount of the foreign currency forward contracts outstanding at January 2, 2005 was approximately $4.0 million. These contracts had a fair value of approximately $249,443 and were included in other current liabilities at January 2, 2005. For the year ended January 2, 2005, there were no amounts recognized in earnings due to hedge ineffectiveness and we settled foreign exchange contracts of $283,721. The Company did not hold any derivative ﬁnancial instruments prior to ﬁscal 2004. 4. Warranties and Maintenance Contracts The Company generally provides a one year warranty on genotyping and gene expression systems. At the time revenue is recognized, the Company establishes an accrual for estimated warranty expenses associated with system sales. This expense is recorded as a component of cost of product revenue. Estimated warranty expenses associated with extended maintenance contracts are recorded as cost of revenue ratably over the term of the maintenance contract. F-17 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Changes in the Company’s warranty liability during the two years ended January 2, 2005 are as follows (in thousands): Balance at December 29, 2002*********************************************** Additions charged to cost of revenue ***************************************** Balance at December 28, 2003*********************************************** Additions charged to cost of revenue ***************************************** Repairs and replacements *************************************************** Balance at January 2, 2005 ************************************************** $ — 230 230 976 (629) $ 577 5. Commitments and Long-term Debt Building Loan In July 2000, the Company entered into a 10-year lease to rent space in two newly constructed buildings in San Diego that are now occupied by the Company. That lease contained an option to purchase the buildings together with certain adjacent land that has been approved for construction of an additional building. The Company exercised that option and purchased the properties in January 2002 and assumed a $26 million, 10-year mortgage on the property at a ﬁxed interest rate of 8.36%. The Company made monthly payments of $208,974, representing interest and principal, through August 2004. Interest expense was $1.4 million, $2.2 million and $2.3 million for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. In June, 2004, the Company entered into a conditional agreement to sell its land and buildings for $42.0 million and to lease back such property for an initial term of ten years. The sale was completed in August 2004 at which time the lease was signed. After the repayment of the remaining $25.2 million debt and other related transaction expenses, the Company received $15.5 million in net cash proceeds. The Company removed the land and net book value of the buildings of $36.9 million from its balance sheet, deferred the resulting $3.7 million gain on the sale of the property, and is amortizing the deferred gain over the ten year lease term in accordance with SFAS 13, Accounting for Leases. The Company leased a portion of the space to a tenant under a lease which expired in June 2004. Rental income was recorded as an offset to the Company’s facility costs. Rental income was $409,517, $695,282 and $679,468 for the years ended January 2, 2005, December 28, 2003, and December 29, 2002, respectively. Capital Leases In April 2000, the Company entered into a $3,000,000 loan arrangement to be used at its discretion to ﬁnance purchases of capital equipment. The loan was secured by the capital equipment ﬁnanced. As of January 2, 2005, all loan payments were made, the underlying equipment was purchased and the loan arrangement was closed. Cost and accumulated depreciation of equipment under capital leases at December 28, 2003 was $1,287,789 and $1,060,278, respectively. Depreciation of equipment under capital leases was included in depreciation expense. Interest expense related to capital leases was $10,500, $56,661 and $97,265 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. F-18 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Operating Leases In August 2004, the Company entered into a ten year lease for its San Diego facility after the land and building were sold (as discussed above). Under the terms of the lease, the Company made a $1.9 million security deposit and is paying monthly rent of $318,643 for the ﬁrst year with an annual increase of 3% in each subsequent year. The lease contains an option to renew for three additional periods of ﬁve years each. The Company also leases ofﬁce space under non-cancelable operating leases that expire at various times through January 2007. These leases contain renewal options ranging from 2 to 3 years. At January 2, 2005, annual future minimum payments under these operating leases are as follows (in thousands): 2005 ******************************************************************** 2006 ******************************************************************** 2007 ******************************************************************** 2008 ******************************************************************** 2009 ******************************************************************** 2010 and thereafter******************************************************* Total **************************************************************** $ 4,251 4,371 4,131 4,225 4,351 21,896 $43,225 Rent expense, net of amortization of the deferred gain on sale of property, was $1,794,234, $238,065 and $141,361 for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. 6. Stockholders’ Equity Common stock As of January 2, 2005, the Company had 38,120,685 shares of common stock outstanding, of which 4,844,072 shares were sold to employees and consultants subject to restricted stock agree- ments. The restricted common shares vest in accordance with the provisions of the agreements, generally over ﬁve years. All unvested shares are subject to repurchase by the Company at the original purchase price. As of January 2, 2005, 154,003 shares of common stock were subject to repurchase. Stock Options In June 2000, the Company’s board of directors and stockholders adopted the 2000 Stock Plan. The 2000 Stock Plan amended and restated the 1998 Incentive Stock Plan and increased the shares reserved for issuance by 4,000,000 shares. In addition, the 2000 Stock Plan provides for an automatic annual increase in the shares reserved for issuance by the lesser of 5% of outstanding shares of the Company’s common stock on the last day of the immediately preceding ﬁscal year, 1,500,000 shares or such lesser amount as determined by the Company’s board of directors. In 1998, the Company adopted the 1998 Incentive Stock Plan (the ‘‘Plan’’) and had reserved 5,750,000 shares of common stock for grants under the Plan. The Plan provided for the grant of incentive and nonstatutory stock options, stock bonuses and rights to purchase stock to employees, directors or consultants of the Company. The Plan provided that incentive stock options to be granted only to employees at no less than the fair value of the Company’s common stock, as determined by the board of directors at the date of the grant. Options generally vest 20% one year from the date of grant and ratably each month thereafter for a period of 48 months and expire ten years from date of grant. In December 1999, the Company modiﬁed the plan to allow for acceleration of vesting in the event of an acquisition or merger. F-19 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. A summary of the Company’s stock option activity from December 30, 2001 through January 2, 2005 follows: Options Weighted- Average Exercise Price Outstanding at December 30, 2001 ************************** 3,380,796 Granted *************************************************** 1,467,500 Exercised ************************************************** (137,727) Cancelled ************************************************* (287,788) Outstanding at December 29, 2002 ************************** 4,422,781 Granted *************************************************** 1,241,175 Exercised ************************************************** (102,590) Cancelled ************************************************* (331,492) Outstanding at December 28, 2003 ************************** 5,229,874 Granted *************************************************** 1,453,400 Exercised ************************************************** (139,768) Cancelled ************************************************* (337,486) Outstanding at January 2, 2005 ****************************** 6,206,020 $ 8.97 $ 5.62 $ 0.46 $11.81 $ 7.94 $ 3.31 $ 1.25 $ 8.36 $ 6.95 $ 7.08 $ 1.98 $ 8.80 $ 6.99 At January 2, 2005, options to purchase approximately 2,653,581 shares were exercisable and 5,964,649 shares remain available for future grant. Following is a further breakdown of the options outstanding as of January 2, 2005: Range of Exercise Prices Options Outstanding $0.03 - 3.06 $3.20 - 4.64 $4.87 - 5.99 $6.00 - 7.90 $7.94 - 11.55 $11.56 - 45.00 1,046,528 1,084,251 1,225,679 1,312,994 1,043,316 493,252 6,206,020 Weighted Average Remaining Life in Years Weighted Average Exercise Price Options Exercisable Weighted Average Exercise Price of Options Exercisable 7.05 8.08 7.54 8.56 6.72 5.94 7.50 $ 2.00 $ 4.14 $ 5.78 $ 7.27 $ 9.11 $21.64 $ 6.99 557,690 393,768 315,639 339,664 650,475 396,345 2,653,581 $ 1.43 $ 4.15 $ 5.63 $ 7.05 $ 9.14 $21.92 $ 8.00 F-20 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. 2000 Employee Stock Purchase Plan In February 2000, the board of directors and stockholders adopted the 2000 Employee Stock Purchase Plan (the ‘‘Purchase Plan’’). A total of 2,445,547 shares of the Company’s common stock have been reserved for issuance under the Purchase Plan. The Purchase Plan permits eligible employees to purchase common stock at a discount, but only through payroll deductions, during deﬁned offering periods. The price at which stock is purchased under the Purchase Plan is equal to 85% of the fair market value of the common stock on the ﬁrst or last day of the offering period, whichever is lower. The initial offering period commenced in July 2000. In addition, the Purchase Plan provides for annual increases of shares available for issuance under the Purchase Plan beginning with ﬁscal 2001. 585,855, 304,714 and 128,721 shares were issued under the 2000 Employee Stock Purchase Plan during ﬁscal 2004, 2003 and 2002, respectively. Deferred Stock Compensation Since the inception of the Company, in connection with the grant of certain stock options and sales of restricted stock to employees, founders and directors through July 25, 2000, the Company has recorded deferred stock compensation totaling approximately $17.6 million, representing the differ- ence between the exercise or purchase price and the fair value of the Company’s common stock as estimated by the Company’s management for ﬁnancial reporting purposes on the date such stock options were granted or restricted common stock was sold. Deferred compensation is included as a reduction of stockholders’ equity and is being amortized to expense over the vesting period of the options and restricted stock. During the years ended January 2, 2005, December 28, 2003 and December 29, 2002, the Company recorded amortization of deferred stock compensation expense of approximately $0.8 million, $2.5 million and $4.4 million, respectively. Shares Reserved for Future Issuance At January 2, 2005, the Company has reserved shares of common stock for future issuance as follows (in thousands): 2000 Stock Plan *********************************************************** 2000 Employee Stock Purchase Plan ***************************************** 12,171 1,364 13,535 F-21 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Stockholder Rights Plan On May 3, 2001, the Board of Directors of the Company declared a dividend of one preferred share purchase right (a ‘‘Right’’) for each outstanding share of common stock of the Company. The dividend was payable on May 14, 2001 (the ‘‘Record Date’’) to the stockholders of record on that date. Each Right entitles the registered holder to purchase from the Company one unit consisting of one- thousandth of a share of its Series A Junior Participating Preferred Stock at a price of $100 per unit. The Rights will be exercisable if a person or group hereafter acquires beneﬁcial ownership of 15% or more of the outstanding common stock of the Company or announces an offer for 15% or more of the outstanding common stock. If a person or group acquires 15% or more of the outstanding common stock of the Company, each Right will entitle its holder to purchase, at the exercise price of the right, a number of shares of common stock having a market value of two times the exercise price of the right. If the Company is acquired in a merger or other business combination transaction after a person acquires 15% or more of the Company’s common stock, each Right will entitle its holder to purchase, at the Right’s then-current exercise price, a number of common shares of the acquiring company which at the time of such transaction have a market value of two times the exercise price of the right. The Board of Directors will be entitled to redeem the Rights at a price of $0.01 per Right at any time before any such person acquires beneﬁcial ownership of 15% or more of the outstanding common stock. The rights expire on May 14, 2011 unless such date is extended or the rights are earlier redeemed or exchanged by the Company. 7. Legal Proceedings The Company has incurred substantial costs in defending itself against patent infringement claims, and expects to devote substantial ﬁnancial and managerial resources to protect its intellectual property and to defend against the claims described below as well as any future claims asserted against it. Termination-of-Employment Lawsuit In June 2002, the Company recorded a $7.7 million charge to cover total damages and estimated expenses awarded by a jury related to a termination-of-employment lawsuit. The Company appealed the decision, and in December 2004, the Fourth Appellate District Court of Appeal, in San Diego, California, reduced the amount of the award. The Company recorded interest expense during the appeal based on the statutory rate. For the years ended January 2, 2005 and December 28, 2003, the Company recorded litigation expense of $567,000 and $756,000, respectively, for interest. As a result of the revised judgment, the Company reduced the $9.2 million liability recorded on its balance sheet to $5.9 million and recorded a gain of $3.3 million as a litigation judgment in the statement of operations for the year ended January 2, 2005. As a result of the Company’s decision to appeal the ruling, the Company ﬁled a surety bond with the court equal to 1.5 times the judgment amount or approximately $11.3 million. Under the terms of the bond, the Company is required to maintain a letter of credit for 90% of the bond amount to secure the bond. Further, the Company was required to deposit approximately $12.5 million of marketable securities as collateral for the letter of credit and accordingly, these funds were restricted from use for general corporate purposes until the appeal process was completed. A judgment was rendered in December 2004 and payment was made in early 2005 at which time the restricted funds, recorded as restricted investments, were released. F-22 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Litigation with Applera Corporation’s Applied Biosystems Group In November 1999, the Company entered into a joint development agreement with Applied Biosystems Group (‘‘Applied Biosystems’’), an operating group of Applera Corporation (‘‘Applera’’), under which the companies would jointly develop a SNP genotyping system that would combine the Company’s BeadArray technology with Applied Biosystems’ assay chemistry and scanner technology. In conjunction with the agreement, Applied Biosystems agreed to provide the Company with non- refundable research and development support of $10.0 million, all of which was provided by December 2001. As of December 28, 2003 this amount was recorded as a liability on the Company’s balance sheet. In December 2002, Applied Biosystems initiated a patent infringement suit and sought to compel arbitration of an alleged breach of the joint development agreement. In December 2002, the Company ﬁled a suit alleging breach of contract, breach of the implied covenant of good faith and fair dealing, unfair competition and other allegations against Applied Biosystems in San Diego Superior Court, and moved to prevent the arbitration of the joint development agreement sought by Applied Biosystems. In January 2004, the Company notiﬁed Applied Biosystems that it was terminating the joint develop- ment agreement. In August 2004, the Company and Applera entered into a settlement and cross-license agree- ment. Under the terms of the agreement, the Company paid Applera a one-time payment of $8.5 million. The settlement agreement also provided for an exchange of royalty-free cross-licenses to certain intellectual property rights, termination of the joint development agreement, dismissal of the federal patent infringement action brought by Applied Biosystems, termination of the arbitration proceeding, and dismissal of the Company’s state court action against Applied Biosystems. As a result of the settlement, the Company removed the $10.0 million liability from its balance sheet, made a payment of $8.5 million to Applera and recorded a gain of $1.5 million as a litigation settlement in the statement of operations for the year ended January 2, 2005. Affymetrix Litigation In July 2004, Affymetrix, Inc. (‘‘Affymetrix’’) ﬁled a complaint in the U.S. District Court for the District of Delaware alleging that certain of the Company’s products infringe six Affymetrix patents. The suit seeks an unspeciﬁed amount of monetary damages and a judgment enjoining the sale of products, if any, that are determined to be infringing these patents. In September 2004, the Company ﬁled its answer and counterclaims to Affymetrix’ complaint, seeking declaratory judgments from the court that it does not infringe the Affymetrix patents, and that such patents are invalid, and ﬁled counterclaims against Affymetrix for unfair competition and interference with actual and prospective economic advantage. The Company believes it has meritorious defenses against each of the infringe- ment claims alleged by Affymetrix and intends to vigorously defend itself against this suit. However, the Company cannot be sure it will prevail in this matter. Any unfavorable determination, and in particular, any signiﬁcant cash amounts required to be paid by the Company or prohibition of the sale of the Company’s products and services, could result in a material adverse effect on its business, ﬁnancial condition and results of operations. While the parties have pending motions before the court, no trial date has yet been set for this case. F-23 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. 8. Collaborative Agreements International HapMap Project The Company is the recipient of a grant from the National Institutes of Health covering its participation in the ﬁrst phase of the International HapMap Project, which is a $100 million, internationally funded successor project to the Human Genome Project that will help identify a map of genetic variations that may be used to perform disease-related research. The Company could receive up to $9.1 million of funding for this project which covers basic research activities, the development of SNP assays and the genotyping to be performed on those assays. As of January 2, 2005, the Company had approximately $0.7 million of funding remaining related to this project which is expected to be received in early 2005. Invitrogen Corporation In December 2004, the Company entered into a strategic collaboration with Invitrogen Corpora- tion. The collaboration is expected to expand the Company’s Oligator DNA synthesis technology and combine that capability with Invitrogen’s sales, marketing and distribution channels. Under the terms of the agreement, Invitrogen has agreed to pay the Company up to $3.4 million, which the Company plans to invest in its San Diego facility to enable implementation of fourth-generation Oligator technology and extend the technology into tube-based oligo products. In addition, the agreement provides for the transfer of the Company’s Oligator technology into two Invitrogen facilities outside North America. Proﬁt from the sale of collaboration products will be divided equally between the two companies. 9. Income Taxes The Company’s provision for income taxes for the years ended January 2, 2005 and December 28, 2003 consisted of $135,000 of income tax expense related to its foreign operations. This expense is included with interest and other expense in the statement of operations. At January 2, 2005, the Company has federal and state tax net operating loss carryforwards of approximately $86.5 million and $39.1 million, respectively. The federal and state tax loss carryfor- wards will begin expiring in ﬁscal year 2018 and 2006 respectively, unless previously utilized. The Company also has federal and state research and development tax credit carryforwards of approxi- mately $3.1 million and $3.0 million, respectively, which will begin to expire in ﬁscal year 2018, unless previously utilized. Pursuant to Sections 382 and 383 of the Internal Revenue Code, annual use of the Company’s net operating loss and credit carryforwards may be limited in the event of a cumulative ownership change of more than 50 percentage points within a three-year period. F-24 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. Signiﬁcant components of the Company’s deferred tax assets as of January 2, 2005 and December 28, 2003 are shown below (in thousands). A valuation allowance has been established as of January 2, 2005 and December 28, 2003 to offset the net deferred tax assets, as realization of such assets has not met the ‘‘more likely than not’’ threshold required under FAS 109. January 2, 2005 December 28, 2003 Deferred tax assets: Net operating loss carryforwards **************************** $ 32,161 Research and other credit carryforwards ********************* 5,076 Advance payment from former collaborator ****************** — Capitalized research and development ********************** 1,857 Other **************************************************** 6,433 Total deferred tax assets ********************************* Valuation allowance for deferred tax assets********************* Net deferred taxes ****************************************** $ 45,527 (45,527) — $ 25,869 5,111 4,074 1,348 6,795 43,197 (43,197) $ — Deferred tax assets of approximately $0.4 million and $0.2 million at January 2, 2005 and December 28, 2003, respectively, resulted from the exercise of employee stock options. When recognized, the tax beneﬁt of these assets will be accounted for as a credit to additional paid-in capital rather than a reduction of the income tax provision. Reconciliation of the statutory federal income tax to the Company’s effective tax (in thousands): Year Ended January 2, 2005 Year Ended December 28, 2003 Year Ended December 29, 2002 Tax at federal statutory rate ******************** State, net of federal beneﬁt******************** Research and development credits ************* Change in valuation allowance ***************** Permanent differences************************* Other *************************************** Tax expense********************************** $(2,179) (336) 34 2,330 (264) 550 $ 135 $ (9,472) (1,434) (1,374) 12,130 738 (588) $ — $(14,116) (2,115) (1,239) 14,241 1,234 1,995 $ — On October 22, 2004, the President signed the American Jobs Creation Act of 2004 (the ‘‘Act’’). The Act creates a temporary incentive for U.S. corporations to repatriate accumulated income earned abroad by providing an 85 percent dividends received deduction for certain dividends from controlled foreign corporations. The deduction is subject to a number of limitations and, as of today, uncertainty remains as to how to interpret numerous provisions in the Act. Based on our analysis of the Act, although not yet ﬁnalized, it is possible that under the repatriation provision of the Act we may repatriate some amount of our undistributed foreign earnings. We expect to ﬁnalize our assessment in 2005. 10. Retirement Plan The Company has a 401(k) savings plan covering substantially all of its employees. Company contributions to the plan are discretionary and no such contributions were made during the years ended January 2, 2005, December 28, 2003 and December 29, 2002. F-25 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. 11. Segment Information, Geographic Data and Signiﬁcant Customers The Company has determined that, in accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information it operates in one segment as it only reports operating results on an aggregate basis to chief operating decision makers of the Company. The Company had sales in the following regions for the years ended January 2, 2005, December 28, 2003 and December 29, 2002 (in thousands): January 2, 2005 December 28, 2003 December 29, 2002 United States ********************************* Europe *************************************** Asia ****************************************** Other **************************************** Total *************************************** $24,166 12,528 9,703 4,186 $13,666 5,909 5,557 2,903 $50,583 $28,035 $ 8,731 1,047 246 16 $10,040 Exclusive of revenue recorded from the National Institutes of Health, the Company had one customer that provided approximately 14% of total revenue in the year ended January 2, 2005 and approximately 18% of total revenue in the year ended December 28, 2003 and one other customer that contributed approximately 22% of revenue in the year ended December 29, 2002. Revenue from the National Institutes of Health accounted for approximately 13%, 21% and 19% of total revenue for the years ended January 2, 2005, December 28, 2003 and December 29, 2002, respectively. 12. Subsequent Events In February 2005, the Company signed a deﬁnitive agreement and plan of merger with CyVera Corporation, a privately-held Connecticut-based company, pursuant to which CyVera will become a wholly-owned subsidiary of the Company. CyVera’s technology is highly complementary to our portfolio of products and services and upon closing of the transaction will become an integral part of our technology. The aggregate consideration for the transaction is $17.5 million, consisting of approximately 1.5 million shares of the Company’s common stock and the payment of approximately $2.3 million of CyVera’s liabilities at the closing. The closing is subject to customary conditions and is expected to occur by the end of March 2005. The Company expects the ﬁrst products based on CyVera’s technology to be available in the second half in 2006. F-26 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) ILLUMINA, INC. 13. Quarterly Financial Information (unaudited) The following ﬁnancial information reﬂects all normal recurring adjustments, except as noted below, which are, in the opinion of management, necessary for a fair statement of the results of interim periods. Summarized quarterly data for ﬁscal 2004 and 2003 are as follows (in thousands except per share data): First Quarter Second Quarter Third Quarter Fourth Quarter 2004: Total revenues ************* Total cost of revenue ******* Net income (loss) ********** Historical net loss per share, basic******************** Historical net loss per share, diluted ****************** 2003: Total revenues ************* Total cost of revenue ******* Net loss ******************* Historical net loss per share, basic and diluted********* $10,803 2,802 (3,931) (0.12) (0.12) $ 4,276 1,910 (8,960) $11,486 3,067 (3,516) (0.10) (0.10) $ 4,769 2,026 (8,592) $13,512 3,517 (2,026) (0.05) (0.05) $ 8,249 2,681 (5,511) $14,782 3,873 3,248 0.09 0.08 $10,741 3,420 (4,000) (0.28) (0.27) (0.17) (0.12) In the third quarter of 2004 the Company recorded a $1.5 million reduction in expense for a legal settlement and in the fourth quarter of 2004, the Company recorded a $3.3 million reduction in expense related to the reduction of a legal judgment (see Note 7). F-27 SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS AND RESERVES FOR THE THREE YEARS ENDED JANUARY 2, 2005 Balance at December 30, 2001 ************************ Charged to expense******************************** Utilizations***************************************** Balance at December 29, 2002 ************************ Charged to expense******************************** Utilizations***************************************** Balance at December 28, 2003 ************************ Charged to expense******************************** Utilizations***************************************** Balance at January 2, 2005**************************** Allowance for Doubtful Accounts Reserve for Obsolete and Excess Inventory (Thousands) Reserve for Product Warranty $ 32 115 (2) 145 118 (85) 178 49 (81) $ — 73 — 73 466 (73) 466 543 (407) $ — — — — 230 — 230 976 (629) $146 $ 602 $ 577 F-28 06414_AR_Cvr_20 5/6/05 12:50 PM Page 2 Illumina is keeping customers on the leading edge of research by enabling better performance, higher value, and multiple applications on a single microarray platform. 4 QUARTERS OF SEQUENTIAL REVENUE GROWTH (IN MILLIONS OF DOLLARS) 14 QUARTERS OF SEQUENTIAL REVENUE GROWTH (IN MILLIONS OF DOLLARS) $14.8 $10.7 $10.8 $11.5 $13.5 7 $0.8 $1.3 $1.9 $3.0 $8.2 $3.9 $4.3 $4.8 $14.8 $13.5 $10.7 $10.8 $11.5 $8.2 Q4 2001 Q1 2002 Q2 2002 Q3 2002 Q4 2002 Q1 2003 Q2 2003 Q3 2003 1 $0.7 $0.8 $1.3 $1.9 Q4 2003 $3.0 $3.9 Q1 2004 $4.3 Q2 2004 $4.8 Q3 2004 Q4 2004 Q3 2001 Q4 2001 Q1 2002 Q2 2002 Q3 2002 Q4 2002 Q1 2003 Q2 2003 Q3 2003 Q4 2003 Q1 2004 Q2 2004 Q3 2004 Q4 2004 Corporate Directory Corporate Information BOARD OF DIRECTORS Jay T. Flatley President, Chief Executive Officer and Acting Chief Financial Officer Illumina CORPORATE HEADQUARTERS 9885 Towne Centre Drive San Diego, CA 92121 +1 858.202.4500 www.illumina.com INDEPENDENT ACCOUNTANTS Ernst & Young LLP San Diego, CA 92101 John R. Stuelpnagel, D.V.M. Senior Vice President and Chief Operating Officer Illumina Daniel M. Bradbury Chief Operating Officer Amylin Pharmaceuticals Karin Eastham Executive Vice President and Chief Operating Officer The Burnham Institute Paul Grint, M.D. Senior Vice President and Chief Medical Officer Zephyr Sciences, Inc. William H. Rastetter, Ph.D. Executive Chairman Biogen Idec David R. Walt, Ph.D. Robinson Professor of Chemistry Tufts University EXECUTIVE OFFICERS Jay T. Flatley President, Chief Executive Officer and Acting Chief Financial Officer John R. Stuelpnagel, D.V.M. Senior Vice President and Chief Operating Officer David L. Barker, Ph.D. Vice President and Chief Scientific Officer Paulette D. Cabral Vice President of Human Resources David C. Douglas Vice President of Manufacturing Noemi C. Espinosa Vice President of Intellectual Property Scott D. Kahn, Ph.D. Vice President and Chief Information Officer Robert C. Kain Vice President of Engineering Alan Kersey Vice President and Site General Manager Tristan Orpin Vice President of Worldwide Sales TRANSFER AGENT EquiServe Trust Company N.A. 150 Royall Street Canton, MA 02121 +1 781.575.3400 www.equiserve.com LEGAL COUNSEL Heller Ehrman LLP Menlo Park, CA 94025 FORM 10-K Included with this report is a copy of the Company’s Form 10-K filed with the Securities and Exchange Commission. Additional copies are available by contacting Illumina’s Investor Relations Department. www.illumina.com investor@illumina.com +1 858.202.4750 ANNUAL MEETING The Company’s Annual Meeting of Stockholders will be held at the Company’s corporate headquarters at 10:00 a.m. on June 28, 2005. SELECTED COMMON STOCK DATA The Company’s common stock, par value $.01, has been traded under the symbol ILMN since July 28, 2000 on the NASDAQ National Market. As of May 2, 2005, there were approximately 312 record holders of the Company’s common stock. The Company has not paid any cash dividends since its inception and does not anticipate paying any cash dividends in the foreseeable future. “Safe Harbor” Statement under the Private Securities Litigation Reform Act 1995: this release may contain forward-looking state- ments that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina’s litigation with Affymetrix, the Company’s ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company’s collaboration with Invitrogen, Illumina’s ability to further develop and commercialize its Infinium assay and BeadArray platform technologies, to deploy new gene expression and genotyping products and applications for its platform technolo- gy, to manufacture robust Sentrix® arrays and Oligator® oligonu- cleotides, and other factors detailed in the Company’s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public confer- ence calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward- looking statements beyond the date of this release. © 2005, Illumina, Inc. All rights reserved. Illumina, BeadArray, Array of Arrays, Sentrix, GoldenGate, DASL, Infinium, Making Sense Out of Life and Oligator are trademarks of Illumina, Inc. Printed in the U.S.A. 070-2004-009. 06414_AR_Cvr_19 5/6/05 11:00 AM Page 1 I L L U M N A I , I N C . 2 0 0 4 A N N U A L R E P O R T T H E L E A D I N G E D G E O F G E N E T I C A N A LY S I S Illumina, Inc. 9885 Towne Centre Drive San Diego, CA 92121 www.illumina.com 2004 Annual Report

Continue reading text version or see original annual report in PDF format above